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Abstract 
The research presented in this thesis is motivated by the aim to employ microfluidic devices 
for high-throughput analysis. Two applications, in particular, have been explored: 
diagnostics and environmental sensing. Miniaturization and multiplexing of laboratory 
procedures leads to a decrease of the cost and response time of the test. Moreover 
miniaturization allows the system to become portable, enabling use in the field without 
bulky external equipment. This need is paving the way for innovative approaches and 
microfluidics can be a suitable substitute for standard bench top techniques. In order to be 
appealing, these new technologies should have the same or even better performances over 
the standard techniques, not only in terms of time and cost, but also quality of results. 
First, we developed a multilayer microfluidic platform for high-throughput immunoassay 
analysis. The device is composed of 384 units, each of them containing 4 mechanically 
induced trapping of molecular interactions (MITOMI) buttons, where the interaction of 
antibodies and antigens occurs. Therefore, the platform allows us to perform 1'536 tests, and 
we show that it can be useful for large scale screening in order to identify functional 
antibody pairs. However this system has two limitations: the experimental time (~10 hours) 
and the sensitivity (pM). In the second part, we presented another device modified in order 
to overcome the aforementioned drawbacks and to become more suitable for point of care 
applications.  
This new version of the device has 16 independent units, and the MITOMI buttons are 
patterned with femtoliter wells for digital analysis. We show how digital ELISA improves 
the sensitivity and allows us to detect down to fM concentrations in human serum. We also 
show how the combination of both digital and analog detection can broaden the dynamic 
range. A portable automatic controller has also been built to control the valves and the flow 
throughout the chip and a USB microscope has been exploited in order to measure the 
fluorescent signal. 
In the last part we present a different application for high-throughput microfluidic-based 
devices. A microfluidic device composed of 769 units has been developed for bacterial cell 
?viii 
culture and environmental monitoring. Each unit can be considered as a pixel and the entire 
device as a biodisplay. Each unit contains a specific bacterial strain, which is deposited using 
microspotting techniques. We show how different bacterial strains can be cultured over time 
without contamination between pixels and how they can be monitored after induction. Cells 
can be spotted according to a specific pattern on the chip and express fluorescent protein 
reporters in the presence of specific molecules allowing an easy to interpret result of the test. 
For example, the image of a “skull and crossbones” appears if the analyzed sample is 
contaminated with arsenic. 
Overall, the presented work provides several microfluidic platforms for high-throughput 
analysis of clinical or environmental samples; these devices are useful tools for the study of 
a large number of proteins and molecular diagnostic applications and to characterize 
bacterial strains and environmental monitoring.  
 
 
Keywords: microfluidics, sandwich immunoassay, digital ELISA, diagnostics, point-of-care, 
high-throughput, bacterial culturing, bioreporter, biopixel, environmental monitoring. 
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Riassunto 
Il lavoro di ricerca presentato in questa tesi ha come obiettivo l’utilizzo di dispositivi 
microfluidici per analisi high-throughput. In particolare, sono state esplorate due 
applicazioni: la diagnostica e l’analisi di campioni ambientali. 
La miniaturizzazione e la parallelizzazione di procedure normalmente svolte in laboratorio 
porta a una diminuzione dei costi e dei tempi di analisi. Inoltre la riduzione di dimensioni 
permette di avere un sistema portabile e di svolgere le analisi senza l’utilizzo di 
strumentazioni da laboratorio costose e ingombranti. La necessità di avere un tale dispositivo 
apre la strada ad approcci alternativi e la microfluidica è una buona candidata per soddisfare 
tale richiesta. Queste nuove tecnologie, per essere prese in considerazione, devono fornire 
uguali se non migliori prestazioni, non solo in termini di costi e tempi di analisi, ma anche 
per quanto riguarda la qualità dei risultati. 
Inizialmente abbiamo sviluppato un dispositivo microfluidico multistrato che permette di 
realizzare molteplici analisi immunologiche in parallelo. Il dispositivo è composto da 384 
unità, ogni unità contiene 4 membrane circolari, chiamate MITOMI, che servono ad 
intrappolare meccanicamente su un substrato vetroso le molecole e a studiare l’interazione 
tra antigene e anticorpo. Il dispositivo permette di eseguire 1'5536 test, e può essere 
utilizzato per analizzare un numero elevato di proteine contemporaneamente e studiare la 
funzionalità di differenti coppie di anticorpi. Questo dispositivo ha due limitazioni: il tempo 
necessario per compiere l’analisi (all’incirca 10 ore) e la sensitività (pM). Nella seconda 
parte della tesi verrà descritto, quindi, un innovativo design del dispositivo, realizzato per 
ovviare a queste due limitazioni. 
La nuova versione del dispositivo contiene 16 unità; in questo caso le membrane 
MITOMI hanno delle camerette della dimensione dei femtolitri dove verranno effettuati 
saggi di immunoassorbimennto legato ad enzimi (ELISA) digitali dei campioni. Abbiamo 
mostrato come questa tecnica permette di migliorare la sensitività, raggiungendo una 
risoluzione di fM in siero umano, e che la combinazione di saggio immunologico digitale e 
analogico ha portato ad un aumento dell’intervallo dinamico. È stato inoltre realizzato un 
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controllore automatico e portabile per manipolare le valvole e fluire i liquidi nel dispositivo 
microfluidico. Per l’acquisizione del segnale fluorescente è stato utilizzato un microscopio 
commerciale USB. 
Nell’ultima parte, sarà presentato un dispositivo microfluidico utilizzato per 
un’applicazione diversa dal dosaggio immunologico. Il dispositivo contiene 769 unità ed è 
stato sviluppato per eseguire colture batteriche e per il monitoraggio di campioni ambientali. 
L’intero dispositivo può essere considerato come un display e ogni unità come dei pixel, nei 
quali differenti ceppi batterici sono depositati attraverso un robot. Questi differenti tipi di 
cellule possono crescere durate un esteso periodo, senza avere contaminazioni tra le diverse 
unità, e possono essere monitorate dopo essere state indotte. Le cellule, modificate 
geneticamente per esprimere una proteina fluorescente alla presenza di determinate 
molecole, possono essere poste nelle diverse unità secondo uno specifico pattern. Ad 
esempio l’immagine di un teschio può essere visualizzata se dell’arsenico è presente nel 
campione analizzato con il dispositivo. 
Nel complesso, il lavoro presentato in questa tesi consiste nella realizzazione di dispostivi 
microfluidici per eseguire analisi high-throughput di campioni clinici e ambientali; questi 
dispositivi sono strumenti utili per lo studio di un numero elevato di proteine, la diagnostica 
e per l’analisi di un numero elevato di differenti ceppi batterici e per monitoraggio 
ambientale. 
 
Parole chiave: microfluidica, dosaggio immunologico, ELISA digitale, diagnostica,  
point-of-care, high-throughput, coltura batterica, bioreporter, biopixel, monitoraggio 
dell’ambiente. 
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Résumé 
Les travaux de recherche présentés dans cette thèse ont pour objectif l'utilisation de 
dispositifs microfluidiques à des fins d’analyse en « high-throughput » (haut débit). En 
particulier, deux applications ont été explorées: le diagnostic médical et l'analyse des 
échantillons environnementaux. 
La miniaturisation et la parallélisassions des procédures normalement effectuées dans le 
laboratoire conduit à une diminution des coûts et des durées d’analyse. En outre, la réduction 
de la taille permet d'avoir un système portable et d'effectuer l'analyse sans l'utilisation 
d'instruments de laboratoire coûteux et encombrants. La nécessité d'avoir un tel dispositif au 
développement d’approches alternatives, et la microfluidique est une technologie 
prometteuse pour remplacer des techniques actuelles en répondant aux critères évoqués plus 
haut. Afin que ces nouvelles technologies soient attrayantes, elles se doivent de fournir une 
performance égale ou supérieure, non seulement en termes de coût et de temps d'analyse, 
mais également en ce qui concerne aussi la qualité des résultats. 
Nous avons développé initialement un dispositif microfluidique multicouche qui permet 
d'effectuer plusieurs tests immunologiques en parallèle. Le dispositif se compose de 384 
unités, chaque unité comprenant 4 boutons membranes circulaires, appelés MITOMI, qui 
servent à piéger mécaniquement sur un substrat de verre des molécules et ainsi étudier 
l'interaction entre un antigène et un anticorps. Le dispositif permet d'effectuer 1'536 tests. Il 
peut donc être utilisé pour analyser un grand nombre de protéines et en même temps étudier 
la fonctionnalité de différentes paires d'anticorps. Ce dispositif a toutefois deux limites: le 
temps nécessaire pour effectuer l'analyse (environ 10 heures) et la sensibilité du test 
immunologique (pM).  
Dans la deuxième partie de la thèse, une conception innovante du dispositif est décrite, 
conçue pour surmonter les deux limites évoquées. La nouvelle version du dispositif contient 
16 unités; dans ce cas, les boutons MITOMI comportent des puits de quelques femtolitres 
dans lesquels seront effectués des dosages d’échantillons par méthode immuno-enzymatique 
ELISA sous forme digitale. Nous montrons que cette technique améliore la sensibilité, avec 
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une résolution atteignant de fM dans le sérum humain, et que la combinaison des analyses 
digitale et analogique conduit à une augmentation de la gamme dynamique du test 
immunologique. Nous présentons également un dispositif de commande automatique et 
portable pour manipuler les valves et le débit du liquide dans le dispositif microfluidique, 
ainsi que l’utilisation d’un microscope commercial USB pour l'acquisition du signal 
fluorescent Dans la dernière partie, nous présentons un dispositif microfluidique utilisé pour 
une application qui diffère du dosage immuno-enzymatique. Le dispositif, contenant 769 
unités, a été développé pour effectuer des cultures bactériennes et pour la surveillance des 
échantillons environnementaux (par exemple d'eau). L'ensemble du dispositif peut être 
considéré comme un écran, et chaque unité comme un pixel, dans lesquels les différentes 
souches bactériennes sont déposées par l'intermédiaire d'un robot « spotter ». Ces différents 
types de bactéries peuvent se développer sur une longue période, sans contamination entre 
les différentes unités, et peuvent être surveillées après induction. Les bactéries 
génétiquement modifiées pour exprimer une protéine fluorescente en présence de certaines 
molécules peuvent être placées dans les différentes unités selon un motif spécifique. Par 
exemple, le symbole de la tête de mort peut être affiché si l'arsenic est présent dans 
l'échantillon analysé avec l'appareil. 
Dans l'ensemble, les travaux présentés dans cette thèse consistent en la réalisation de 
dispositifs microfluidiques pour l’analyse à haut débit d'échantillons cliniques, utiles pour 
l'étude d'un grand nombre de protéines et pour l’analyse diagnostique; ainsi 
qu’environnementaux pour la surveillance environnemental et l’étude de souches 
bactériennes. 
 
 
 
Mots-clés: microfluidique, test immunologique, ELISA numerique, diagnostic,  
point-of-care, high-throughput, culture bactérienne, bioreporter, biopixel, surveillance de 
l'environnement. 
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  Chapter 1
Introduction 
The detection and quantification of proteins is extremely important to describe biological 
processes and for clinical analysis. In particular for clinical analysis the quantitation of 
biomarkers is crucial for diagnosis, monitoring health conditions and verifying the efficacy 
of a drug. With standard laboratory test equipment significant consumption of reagents, 
sample and time are required in order to perform the analysis. In order to overcome those 
limitations, the development of a miniaturized system, able to perform procedures that are 
usually done in a laboratory became highly attractive. Miniaturized devices speed up the 
analysis test and dramatically reduce the overall cost of the process, making the practice of 
diagnostics faster, cheaper and more accessible to people. Moreover, the possibility to have 
information about multiple biomarkers has stimulated the development of analysis that 
provides parallel protein measurement in the same specimen [1]. 
Microfluidics in the last decades has been extensively explored and is a good candidate to 
replace standard laboratory techniques [2]. Microfluidics manipulates and controls liquids in 
a range of microliters to picoliters, having channels with dimensions in the micro-scale, and 
all the fluidic components are miniaturized and integrated in the same device. Small 
dimensions lead not only to small volumes of reagents but also to specific physical 
properties: mass transport is dominated by diffusion, there is no turbulence, extremely well-
designed and predictable laminar flow is attainable and it is possible to guarantee 
homogenous experimental conditions within different units of the same chip [3], [4].  
The number of publications, based on microfluidic research, especially in engineering 
journals, is increasing more and more over the years [5], showing how microfluidics has 
been applied to a variety of fields: single molecule analysis [6], diagnostics [7], organ on a 
chip [8], synthetic biology [9], [10], genomics and biomaterials [11]. Despite the effort on 
microfluidic-based research, there is still room for improving the technology in order to 
commercialize such devices. 
 
Chapter 1 – Introduction 
?2 
1.1 - Multilayer microfluidics  
Microfluidics consists of an analytical system for the manipulation of small volumes of 
liquids (pL or nL). As already mentioned, small dimensions lead to small sample volumes 
but also to an improvement in the performance compared to the macroscale system, and 
most importantly increase the number of individual experiments per time. 
Microfluidic components can be fabricated with the same techniques developed for 
microelectronics and semiconductor-processing industries. The dimensions of the features 
are not highly critical (?m) and the process flow is straightforward. Different materials can 
be employed for the fabrication of microfluidic devices: glass, silicon, paper, hydrogels and 
elastomers [12]. Glass and silicon are normally processed with standard photolithography. 
Glass is transparent, electrically insulating and not permeable to gas. Some advantages over 
other materials include its compatibility with solvents and thermo stability; however there 
are some disadvantages such as the complexity and cost of fabrication. Hydrogels are widely 
used to embed cells, since they can mimic the extracellular matrix. Thus, their aqueous 
nature, permeability and biocompatibility make them suitable for 3D cell culture. Paper 
devices are made on a porous matrix of cellulose; their mode of operation is based on 
capillary effect. Modifying some areas of the paper, it is possible to guide the liquid. These 
devices are simple, they can be employed for fast analysis and they do not need an external 
pump to flow the liquid, but on the other hand they are low-throughput and they have low 
sensitivity. It is also possible to combine the different materials into a hybrid chip and 
benefit from their individual advantages [13], [14]. 
Polymer-based chips were introduced several years after glass microfluidic devices. They 
are less expensive, compared to glass devices and thanks to soft-lithography, they are rapidly 
fabricated and can be easily replicated using the same mold. One of the most popular 
elastomers is polydimethylsiloxane (PDMS) [11]. One advantage of PDMS is its high 
elasticity, which allows the integration of pneumatic valves in the chip, enabling precise 
control of multiple liquids in the device [16]. The valves are obtained by bonding multiple 
patterned layers of PDMS and aligning the channels of one layer (the control) perpendicular 
to the channels of the other layer (flow layer). Since PDMS is a soft material, it is possible to 
obtain large deflections by applying small forces, thus applying pressure in the control line 
causes the PDMS membrane to bend and pinch the flow channel underneath. Thousands of 
different valves can be integrated in a single device yielding a microfluidic large-scale 
integration (MLSI) device [17]. PDMS has other advantages like optical transparency, thus it 
is suitable for optical detection, and it is permeable to gas and biocompatible. Despite all 
these qualities, PDMS has also some limitations, such as incompatibility with organic 
solvents. 
1.2 - Microfluidic for immunoassay-based diagnostic 
Immunoassays are widely used for medical diagnostics; they are based on the high affinity 
and specificity between antigen and antibody. Immunoassays relay on the ability of an 
antibody to specifically bind target molecules, the antigens. Once the target molecule binds 
the primary antibody, a secondary labeled antibody is added in order to detect the 
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immunocomplex. Possible labels for the secondary antibodies are: enzymes, radioactive 
isotopes, DNA reporters, fluorogenic reporters or electrochemiluminescent tags. 
Immunoassays are usually performed on a microwell plate, but they could be significantly 
improved with microfluidics. There are important characteristics a device should have to 
perform a good diagnosis and compete with standard diagnostic techniques: multiplexing, 
sensitivity, broad dynamic range, low sample consumption and portability.  
Multiplexing enables the analysis of different samples  or the identification of different 
biomarkers within the same sample [18] but also the study of the interactions between 
multiple proteins and the discovery of new biomarkers [19]. There are two approaches for 
multiplex assay using microfluidics: bead based-immunoassay [20] or a planar assay [21]–
[23].  
One example of bead-based assays is the Luminex technology [24]. In this approach 
beads are dyed with different intensity in order to differentiate them from each other and 
individual sets of bead are coated with a specific primary antibody. The beads are then 
incubated with the target molecule allowing the binding with a specific antibody. Then 
secondary labeled antibodies bind the target analyte and the signal is read through flow 
cytometry. The readout is performed in order to identify the color specific to each bead 
corresponding to the specific target and the signal from the secondary antibody to detect the 
immunocomplex. Multiplexing is achieved using a color code for each bead, enabling the 
discrimination of different antigens. 
For the planar assay (for example using microspotting techniques) the multiplexing is 
given by the position of the immunocomplex on the surface. In this case, in different 
positions it is possible to localize different antibodies, thus overcoming the intrinsic 
limitation of having a limited number of colors. Two examples of planar assays are the 
barcode [22] and the mosaic immunosensors [9], [13]. In the former, multiple analytes in a 
blood sample are detected, where the immunoassay area is a microscopic barcode. The latter 
is one of the first examples of a planar assay performed using microfluidics. The surface 
where the assay occurs was patterned using microchannels to guide the solution containing a 
specific antigen in a specific position of the substrate.  
Another approach for planar assay is the Mechanically Induced Trapping of Molecular 
Interaction (MITOMI)[26]. This technique combines both microarrays and a new 
microfluidic detection mechanism [27]. Nanoliter-volumes of biological solution are spotted 
on a glass slide and the spots are then aligned with a microfluidic device. The units of the 
microfluidic chip have some characteristic components: a spotting chamber, a detection 
chamber, a “neck valve” that separates the two chambers and a “sandwich valve” that 
separates each unit from the neighboring ones. Inside the detection area there are one or 
more button membranes that physically trap molecules that bind the surface between the 
substrate and the PDMS. MITOMI has been originally used to study the affinity and the 
kinetic interactions between molecules, but it has also been used as a diagnostic tool for 
immunoassay tests [6], [10], [15]. 
Both bead and planar approaches have enabled multiplex analysis but they require the 
detection of the signal from a large number of reporter molecules, which limits their 
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sensitivity. Moreover a large number of secondary antibodies is needed to increase the signal 
above the background for detection. As it will be explained in detail in the next paragraph, a 
possible solution to increase the limit of detection (LOD) involves using digital enzyme-
linked immunoassorbent assay (ELISA). 
A miniaturized immunoassay based-device can be employed as a point of care (POC), 
usually referring to small portable devices that can autonomously carry out immunoassays 
without bulky external equipment. Microfluidic-based immunoassays are emerging as good 
candidates that can accomplish this requisite [30]. For example an automated microfluidic 
liquid handling system controlled by a smartphone has been developed [31]. The controller 
is able to manipulate valves and liquids within an elastomeric microfluidic device; the 
system is portable and powered by a 12.8 V 1500 mAh Lithium battery. 
Another important requirements for POC applications is the possibility to utilize small 
sample volumes and avoid any pre-treatment of the sample. Thanks to microfluidic 
techniques, it is possible to drastically reduce sample consuption, because of the small 
device dimensions and the capability to perform several different tests on the same device. 
Ideally a POC device should required only one drop of blood (~5 ?l) obtainable by a simple 
pin-prick to perform the test. 
1.2.1 - Digital immunoassay 
As already mentioned, one challenge for diagnostics using microfluidics is the capability of 
detecting low concentrations of analyte to identify the early onset of a disease.  
A method to obtain high sensitivity is digital ELISA. ELISA is an enzyme immunoassay, 
where the detection antibody is linked to an enzyme. After the immunocomplex with the 
antigen is formed, the conjugate enzyme is incubated with substrate and the product activity 
is monitored. The idea is to compartmentalize the immunocomplex in a small volume 
(femtoliters, fl) chamber and monitor the activity of the enzyme over time. If the reaction 
volume is small, a small number of fluorophores produced by the enzymatic reaction, is 
enough to have a signal above the background [32]. Thus, confining the molecules in a small 
volume leads an increase in concentration and thus in sensitivity (Figure 1.1a).  
If the sample has a low concentration of analyte, the ratio of the target molecule to the 
number of binding sites (captured antibodies) is small and the probability that a reaction 
volume contains a labeled immunoassay complex follows a Poisson distribution. According 
to this distrubution, an event (in our case the formation of the immunocomplex) can occur 0, 
1, 2, … times in an interval. If ? is the average number of events in an interval, the 
probability of observing k events in an interval (in our case the number of target molecules) 
is given by the equation: 
 
 ? ? ? ?
????
??  
Equation 1-1 
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According to Poisson distribution, when we decrease the concentration of the analyte, the 
probability of having, in each reaction volume, either 1 or 0 immunocomplex, increases. 
Each small volume reaction can then be categorized as “on” for a reactor containing one 
enzyme and “off” for one where the biomolecule is not present (Figure 1.1b) [33]–[35]. 
Time-lapses are taken and the concentration of the analyte is calculated according to the 
number of “on” wells over the total number of wells. The activity traces of enzymes are 
plotted over time and the slope for each curve is observed (the greater number of enzymes, 
the steeper the slope). A histogram with the observed turnover rate for each well versus the 
number of wells can be plotted [36]. It is then possible to approximate each histogram peak 
with a Gaussian distribution and calculate the probability to have 0, 1, 2, 3… molecules 
(Figure 1.1c). 
 
 
Figure 1.1 Digital detection: a) Representation of the difference in fluorescence signal 
between a molecule in a large (top) and small volume (bottom). b) Schematic of the digital 
signal related to increasing concentration. c) Activity of the enzyme molecules: recording of 
the enzyme activity in different wells (on the left), histogram of the number of chambers 
plotted versus the increase in concentration over 60 s, the value displayed next to each peak is 
the center of the Gaussian (in the center), four peaks can be attributed to an occupancy of 
0,1,2,or 3 enzyme(s) per chamber (on the right). Panel (c) is adapted from Nat. Biotechnol., 
vol. 23, no. 3, pp. 361–365 © (2005). 
?
To reach a low LOD, a sufficient number of wells has to be interrogated. Other important 
parameters to obtain a low LOD are the antibodies used [37] and enzyme substrate 
concentration, which both should be optimized to achieve high sensitivity.  
One method to perform digital ELISA is to have microfabricated wells, to form a large 
array of femtoliter-sized reaction chambers and load them with beads where a sandwich 
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antibody complex is formed out of the device [34]. The immunocomplex is formed covering 
the bead with the capture antibody and subsequent incubation with the target molecule, 
pbiotinylated detection antibody and streptavidin enzyme label. The size of the femtowell 
matches the bead’s size in order to have one bead per well. If the number of analytes is much 
lower than the beads, it is possible to have single molecule detection. 
As it has been mentioned already, multiplex detection is useful for the identification of 
multiple biomarkers in the same sample. For example the detection of multiple cytokines, 
which play an important role for prognosis, diagnosis and response to therapy. Digital 
immunoassay has been also performed for the detection of multiple biomarkers in human 
serum. In this case multiple subpopulations of beads each with a different fluorescent 
signature and specific antibody are incubated together with the sample [38]: four cytokines 
in plasma have been measured using this approach. 
One limitation of the digital immunoassay is the dynamic range, which is limited by the 
number of interrogated wells. When the concentration is such that all wells will be “on”, any 
higher value in concentration cannot be discriminated. In order to overcome these limits the 
sample can be diluted or a combination of digital and analog detection can be implemented. 
?
1.3 - Microfluidic for cell biology 
Cells have dimensions on the order of microns, so they can be easily manipulated and tested 
using microtechnology [39]. Studying biological systems through microfluidic devices has 
several advantages over conventional bench-top systems: low reagent and sample volume, 
precise control and tailored cellular microenvironments, long term monitoring of cells and 
low-cost devices [40], [41]. The small dimension of microfluidics allows to assembly 
multiple cell culture chambers on a single device. Thus, allows high parallelization of 
analysis and high throughput of sample while reducing reagents cost.  
Indeed, in the field of microbiology, microfluidics has been used for several applications, 
for example: culturing and monitoring of cells [42], impedance-based bacterial detection and 
identification [43], bacterial persistence [44], and live cell bacterial sensor [45]. Moreover, it 
has been shown that cells can be locally and selectively sampled using microfluidic probes 
[46] or microfluidic devices [47]; it is possible to create gradients, study chemotaxis [48]–
[50] and adjust precisely the concentration of nutrients or inducers. Thanks to microfluidics 
it is also possible to mimic in vivo conditions [51]–[53] and obtain a 3D stem cell culture 
system. 
Microfluidics is especially suitable for screening large numbers of cells, in fact the 
technologies for high-throughput screening usually involve robotic liquid handling, high-
density microplates, and sophisticated detection schemes. Using microfluidics enables 
different modes to be employed: perfusion flow mode, droplet mode and microarray mode 
[39]. In the perfusion mode the devices have components for introducing the reagents and 
samples into the chip, moving them in different microchannel networks, combining and 
mixing them. For the droplet mode, the reagents are compartmentalized into nanoliter or 
picoliter volumes using a system of water-in-oil emulsion droplets. Finally, the microarray 
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mode consists of a 2D support where materials, such as antibodies, proteins or lipids, which 
interact with the cells, allow their capture and subsequent interrogation [54] or cells are 
directly spotted on the surface [47], [55], [56]. Some examples of microfluidic high-
throughput screening are the study of: cell-cell communication[57], molecular mechanisms 
for signal transduction [58], model transcriptional regulator [47], [59], or protein localization 
[47].  
The possibility to engineer bacteria to recognize the presence of specific molecules in the 
environment can provide advantages over the conventional chromatography technologies 
that are tedious and not portable. Bioreporters produce an easily detectable signal that 
changes upon the level of exposure to the target compound [60], [61]. The bacteria are 
genetically modified in order to couple a sensing element to a reporter gene, which upon 
expression produces a measurable signal. The amount or activity of the protein reporter is an 
indication of the cellular response to the target molecule. 
Having a device that creates an interface between the environment and the biosensor is an 
important tool for environmental sensors, for example for heavy metal detection [62], [63]. 
To employ this system in the field, it is necessary to have a safe interface between the 
genetically modified cells, the user and the environment; furthermore the micro device 
should provide fresh medium and sample to the bacteria over time, in order to achieve 
continuous growth and monitoring.  
?
1.4 - Summary of the thesis 
Microfluidics has the possibility to change the way of sensing analytes, from proteins to 
heavy metals. We developed and characterized microfluidic platforms for high-throughput 
analysis. In particular we have employed multilayer PDMS chips for multiplex 
immunoassays and for monitoring bacterial colonies under different environmental 
conditions. 
Following the overview of the state of art of the high-throughput microfluidic devices 
provided in the introduction, Chapter 2 of the thesis presents a microfluidic platform 
containing 384 unit cells, in which 1'536 independent immunassays can be performed in 
parallel. It can be applied to monitor several cytokines over time, yielding information about 
different factors such as inflammation, cell differentiation, etc. Using microarraying, we 
immobilized different primary and secondary antibody pairs into different units and we 
detected several biomarkers in 4 different samples. The platform has been optimized in 
terms of the concentration at which antibodies were spotted, for both primary and secondary 
antibodies. Moreover a stability test has been performed in order to proof the possibility to 
store the device for extended period of time. The platform has also been used in order to 
perform a combinatory study of antibody pairs purchased from different companies to 
identify optimal antibody combinations. 
After showing the possibility to perform multiplex immunoassays using MITOMI buttons 
we designed a new device that allowed us to decrease the experimental time, enhance 
sensitivity, dynamic range (digital-analog detection), and perform multiplexed analysis on 
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small sample volumes. In Chapter 3 we present a multiplexed digital-analog microfluidic 
platform for the rapid and highly sensitive detection of 3-4 biomarkers in quadruplicate in 16 
independent and isolated microfluidic unit cells requiring only a single 5 ?l whole blood 
sample. A peristaltic pump has been introduced in the chip in order to shorten the mixing 
time of the antibody in comparison to the first generation chip in which mixing occurred via 
diffusion. The MITOMI buttons have been patterned with femtoliter wells for digital 
detection. The digital analysis allowed us to reach a LOD in the low femtomolar range in 
human serum. Moreover, by integrating digital and analog detection we were able to achieve 
a dynamic range of up to 5 orders of magnitude. Finally, we eliminated the need of bulky 
equipment around our microfluidic platform by developing a low-cost, portable hardware 
system to control and readout the microfluidic device and detect anti-Ebola IgG in ultra-low 
volumes of whole blood samples in a multiplexed assay format. This approach can overcome 
one of the limitations preventing the application of microfluidics in the field, where bulky 
and expensive lab equipment might not be available, moving the microfluidic approach 
beyond the clinical point of care settings. 
In Chapter 4 we designed a two-layer microfluidic platform to obtain a bacterial display. 
The display has 768 units where different strains can be cultured and interpreted as a pixel. 
We used microarray spotting in order to address the strains to each chamber. It is possible to 
culture the bacteria for several days providing a continuous supply of fresh medium. 
Moreover using a set of valves placed in the inlets and outlets of the chip, it is possible to 
sample different solutions and switch between them, allowing induction in dynamic 
conditions. Finally we also showed that it is possible to spot the strain in a pattern, which is 
easy to interpret, in order to verify if a given analyte is present in the sample (e.g. arsenic in 
tap water). 
? ?
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?
We present a high-throughput microfluidic platform capable of quantitating up to 384 
biomarkers in 4 distinct samples by immunoassay. The double layers microfluidic device 
contains 384 unit cells, which can be individually programmed with pairs of capture and 
detection antibody. Samples are quantitated in each unit cell by four independent MITOMI 
detection areas, allowing four samples to be analyzed in parallel for a total of 1'536 assays 
per device. We show that the device can be pre-assembled and stored for weeks at elevated 
temperature (40°C) and we performed proof-of-concept experiments simultaneously 
quantitating IL-6, IL-1?, TNF-?, PSA, and GFP. Finally, we show that the platform can be 
used to identify functional antibody combinations by screening 64 antibody combinations 
requiring up to 384 unique assays per device. 
?
2.1 - Introduction 
The precise quantitation of proteins is important in systems biology and is becoming of 
interest in clinical studies. In both cases it is increasingly necessary to monitor dozens if not 
hundreds of proteins per sample, to provide an overview of protein levels in signalling 
networks [1], or to derive higher order correlations in clinical samples [2], [3]. Techniques 
for multiplexed analysis of proteins have therefore attracted considerable attention [4]. 
The classical and still widespread approach for quantitating proteins is based on 
immunoassays, particularly ELISA, which provides high-specificity, sensitivity and dynamic 
range, but is relatively low-throughput and extremely cost-ineffective due to large reagent 
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and sample consumption. To alleviate some of these problems low to medium throughput 
microfluidic methods have been developed for protein quantitation [5]–[7]. Multiplexed 
alternatives to ELISAs have recently been developed including array based detection 
schemes [2], [8] and bead based detection [9]–[11]. These approaches enabled the parallel 
analysis of large numbers of biomarkers. One significant difference between multiplexed 
bead assays and standard ELISAs is the fact that all antibody pairs are allowed to cross-react 
in the multiplexed bead assay, giving rise to potential off-target effects. A recent refinement 
of an array based approach circumvented these limitations using a method called antibody 
co-localization microarray (ACM) which specifically co-localizes antibody pairs using a 
microarrayer and has been used to analyse up to 50 proteins in parallel [12]. Although the 
ACM approach solved the problem of cross-reactivity, showed low limits of detection 
(LODs) and a high dynamic range, it remains difficult to implement. Microwestern arrays 
(MWA) were developed to alleviate some of the various shortcomings of bead-based 
multiplexed analysis, reverse-phase lysate arrays, and mass spectrometry based approaches 
[13]. MWAs are miniaturized and partially automated western blots. With MWAs it is 
possible to analyse 192 proteins in 6 samples for a total of 1'152 measurements. Nonetheless, 
MWAs are difficult to fully automate as all processing steps required for a standard western 
blot such as electrophoretic separation, transfer to a nitrocellulose membrane, and 
development with antibodies are still necessary and the entire process requires 14-24 hours. 
Microfluidic based approaches are appealing alternatives to these existing methods, as all 
fluid handling steps can be integrated and thus automated. A recent microfluidic device 
based on mechanically induced trapping of molecular interactions (MITOMI) [14] could 
analyse 4 biomarkers in 8 samples, or vice versa [6]. We have recently reported highly-
integrated and parallelized microfluidic nanoimmunoassays based on MITOMI coupled to 
sample microarrays, allowing the analysis of 4 biomarkers in 384 samples per device [15] 
and more recently 4 biomarkers in 1'024 human clinical serum samples, for a total of 4'096 
measurements, requiring as little as 5 nL per sample [16]. Here we demonstrate a new 
functional mode enabling the parallel analysis of up to 384 biomarkers in 4 samples, for a 
total of 1'536 measurements per device. In our approach, each antibody pair is isolated in its 
own unit cell, completely eliminating cross-talk. We show that we can achieve good 
sensitivity and high-dynamic range with MITOMI. The approach requires ~5-25 nl (0.45-
2.25 ng) of antibody per assay and is thus extremely cost effective. Antibody suppliers 
generally provide 100 mg of antibody, which is sufficient for ~100'000 assays using our 
approach. We also demonstrate that the device and antibody array can be assembled and 
consequently stored for weeks in ambient conditions prior to use. All processing steps are 
fully integrated on the microfluidic device and can be automated [17]. We measured IL-6, 
IL-1?, TNF-?, PSA, and GFP, in buffer and determined the limit of detection (LOD, > mean 
+ 2 std. deviations of the control) for these 5 proteins to be 4, 4, 30, 15, and 4 pM, 
respectively. We go on to show that the platform can be applied to identify optimal antibody 
combinations of a 3 antibody immunosandwich assay by screening all 64 combinations of 4 
primary biotinylated anti-PSA mouse monoclonal antibodies, 4 secondary anti-PSA rabbit 
poly- and monoclonal antibodies, and 4 tertiary anti-rabbit IgG fluorophore conjugated 
antibodies. We tested multiple titrations of the secondary antibody for each of the antibody 
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combinations to derive precise, quantitative information on the relative binding strength for 
all 64-antibody combinations.  We found that many antibody combinations were 
incompatible and thus non-functional, but nonetheless were able to identify several antibody 
combinations that performed well. The platform should thus find applications were it is 
necessary to perform multiplexed biomarker analysis or in combinatoric screens. 
?
2.2 - Results and Discussion 
2.2.1 - Assay workflow 
The device is fabricated by multilayer soft-lithography [18] and is comprised of two PDMS 
layers (control and flow layer) aligned to an epoxy functionalized glass slide pre-arrayed 
with antibody pairs (Figure 2.1a). A DNA microarrayer was used to array the pairs of 
primary and secondary antibodies, which subsequently are aligned to the unit cells so that a 
microfluidic chamber encloses each antibody spot. The aligned device is bonded to the 
epoxy-coated glass slide by incubating overnight at 40°C (Figure 2.1b). 
The microfluidic design is composed of 384 unit cells [15]. Each unit cell consists of two 
1.7 nl antibody chambers, one for the primary antibody and the other for the secondary 
antibody. A detection chamber is located between the two antibody storage chambers and 
includes 4 detection regions created by MITOMI buttons (120 ?m diameter). Each unit cell 
can be isolated with a microfluidic valve, and the antibody chambers are separated from the 
reaction chamber when the sample is flown through the main channel (Figure 2.1a). 
MITOMI is a micro-mechanical method recently developed to allow the quantitative 
analysis of molecular interactions [14], [19]. MITOMI consists of a freestanding “button” 
membrane, which can be actuated by pneumatic or hydraulic pressure, similarly to standard 
micro-mechanical valves generated by multilayer soft-lithography [18]. When the button 
membrane is actuated it physically contacts a circular area on the glass surface of the 
microfluidic device. When the button membrane is in contact with the glass surface it 
protects the surface from solute and solvent molecules and can thus be used for surface 
patterning [20]. In addition to surface patterning, MITOMI is primarily used to mechanically 
trap surface bound molecules between the derivatized glass surface and the PDMS button 
membrane preventing dissociation of these molecules and thus allowing the precise 
measurement of transient molecular interactions. MITOMI has previously been applied to 
characterizing protein-DNA [14], [21]–[24], protein-RNA [25], [26], protein-protein [27], 
protein – small molecule interactions [26] and kinetic measurements [23], [27]. 
The assay itself is composed of four steps: i) functionalization of the surface, ii) surface 
immobilization of the primary antibody, iii) flow of the sample, iv) incubation with the 
secondary antibody, and readout (Figure 2.1c). To functionalize the surface, a solution of 2 
mg/ml biotin-BSA was flowed through the detection chambers for 20 minutes with the 
buttons open, followed by a wash with 0.005% Tween PBS for 10 minutes. Next 0.5 mg/ml 
neutravidin PBS was flowed for 20 minutes, followed again by a wash step. After this step 
the buttons were actuated in order to specifically protect the detection areas while the 
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remaining surface was passivated with biotin-BSA, which was flowed for 20 minutes 
followed by a wash step. 
 
 
Figure 2.1: Workflow schematic. a) Microfluidic design: the device consists of two PDMS 
layers: flow (blue) and control (red). The chip is an array of eight rows by 48 columns for 384 
unit cells. Each unit cell is composed of: two antibody chambers divided by a reaction 
chamber (1-2), 4 MITOMI buttons (3), a valve that segregates the unit cells (4), a valve that 
separates antibody and reaction chambers (5) and a valve for releasing pressure in the 
antibody chambers (6). b) The PDMS chip is aligned to an epoxy-functionalized slide onto 
which primary and secondary antibodies were spotted. c) Assay details: schematic of the unit 
cell and cross section of a button region: i) functionalization of the surface: BSA-biotin is 
flowed though the chip followed by neutravidin. Next, the buttons are closed and BSA-biotin 
flowed again to passivate all neutravidin molecules except for those located underneath the 
MITOMI buttons, ii) the biotinylated primary antibody is allowed to diffuse into the 
MITOMI detection chamber and is bound by neutravidin immobilizing it in the MITOMI 
detection regions, iii) the sample is flown through the device and antigens are captured by the 
surface immobilized antibodies, iv) finally, the fluorescently labeled secondary antibody is 
allowed to diffuse into the MITOMI area, binds to the antigen if present, and is trapped by 
MITOMI. The entire device is then quantitated using a DNA microarray scanner 
?
Next, the unit cells were isolated and the biotinylated primary antibody allowed to diffuse 
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allow a homogeneous immobilization of the primary antibody. After 2.5 hours the buttons 
were opened for 30 minutes and the biotinylated antibodies were immobilized to the four 
neutravidin coated detection regions. We then closed the MITOMI buttons to protect the 
detection regions from cross-contamination, opened the sandwich valves that previously 
isolated the unit cells, closed the primary antibody chamber, and washed the detection region 
with 0.005% Tween PBS. Four different samples can be measured on the device as each of 
the four MITOMI buttons can be independently actuated. It is thus possible to either 
measure one sample at 4 different dilutions, which increases the dynamic range of the assay, 
or 4 independent samples. Each sample is flowed for 20 minutes, followed by a 10 minutes 
wash step. The MITOMI buttons are actuated during the wash step to prevent dissociation 
and thus loss of antigen, and cross-contamination. Finally, the unit cells are once again 
isolated, and the secondary antibody allowed to diffuse into the detection area for 2.5 hours. 
Each button is then opened sequentially for 20 minutes to allow association of the secondary 
antibody. The sequential opening at this step further reduces any possibility of cross-
contamination between buttons, which is particularly important if independent samples are 
tested. The entire device is then scanned with a standard DNA microarray scanner, and 
antigen is detected and quantitated via the fluorescently labeled secondary antibody. 
2.2.2 - Assay optimization 
The concentrations of the primary and secondary antibody were optimized in order to 
achieve optimal device performance and low limits of detection. We spotted 10 different 
concentrations of primary antibody to maximize signal while minimizing the required 
antibody amounts. After surface functionalization, the primary antibodies were re-hydrated 
and allowed to diffuse into the reaction chamber. We then flowed 30 nM of GFP over all 
four buttons in the open state for 20 minutes. GFP pull-down saturated at a spotted antibody 
concentration of 600 nM (Figure 2.2a), and we consequently spotted all primary antibodies 
at a concentration of 600 nM. Special care was taken to ensure that all four buttons were 
uniformly derivatized with primary antibody, which required keeping the buttons closed 
while the primary antibody was allowed to equilibrate for ~2 hours. Failure to do so gave 
rise to higher antibody densities on the two buttons near the antibody source chamber, which 
could not be remedied with longer incubation times, indicating that the amount of spotted 
antibody is not significantly larger than the amount that can be surface immobilized. 
We next optimized the secondary antibody concentration. Different dilutions of anti-GFP 
secondary antibodies labeled with Alexa Fluor 647 and GFP were spotted on the glass slide 
to simultaneously assess the impact of antigen and secondary antibody concentration. For 
this experiment we simply flowed the primary antibody for 20 minutes at a concentration of 
30 nM. The fluorescence signal from the antibody-antigen-antibody complex (Figure 2.2b) 
began to saturate when the concentration of the secondary antibodies reached a value of 28 
nM. The limit of detection (LOD) is ~10 pM (> mean + 2 std. deviations of the control) and 
a dynamic range of 3 orders of magnitude can be achieved in the range of 1.2-140 nM for the 
secondary antibody. Since the LOD was not significantly different over a secondary 
antibody range of 1.2 – 140 nM we opted to use a concentration of 6 nM, which resulted in 
low levels of non-specific signal, a low LOD, and a good dynamic range. Higher secondary 
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antibody concentrations give rise to higher signal but didn’t improve the LOD. Furthermore, 
the use of lower antibody concentrations can result in cost savings when a very large number 
of assays are to be performed. But since our platform already uses very small quantities of 
antibody per assay these considerations are secondary as a single vial of antibody (100 ?g) is 
sufficient for ~100'000 assays. Nonetheless, higher secondary antibody concentrations do 
perform better when high biomarker levels are to be quantitated, and our platform does allow 
for the parallel use of multiple antibody concentrations in different microfluidic unit cells, 
which is appealing if high-dynamic range samples are to be quantitated. For the following 
multiplex experiments we chose 600 nM and 6 nM for the primary antibody and the 
secondary antibody concentrations, respectively. 
 
 
Figure 2.2: Optimization of antibody concentration. a) Different concentrations of anti-
GFP primary antibody were spotted and 30 nM of GFP was detected with the four buttons 
(error bars are std. dev., n=9). All 4 buttons show identical response profiles and 600 nM was 
chosen as the optimal primary antibody concentration.  b) Intensity of fluorescent signal as a 
function of spotted GFP concentration at 5 different secondary antibody concentrations, the 
primary antibody was flowed at a concentration of 60 nM. The inset shows the same data on a 
log-log scale (error bars are std. dev. n=3). 
?
2.2.3 - Multiplex assay 
To demonstrate the multiplexing capability of the platform, we tested various combinations 
between 5 antibody pairs on a single device for 1'408 experiments (Figure 2.3). GFP primary 
antibody was tested against all 5 secondary antibodies each at two different concentrations 2 
nM and 6 nM, and a BSA negative control, for a total of 11 combinations. These 
combinations were spotted 4 times requiring 44 unit cells. The remaining 4 primary 
antibodies (IL-6, IL-1?, TNF-?, PSA) were tested against 5 different secondary antibodies 
each at two concentrations and one BSA control, but spotted in 7 replicates, requiring a total 
of 308 unit cells. In total, 352 unit cells on the device were used in this experiment. We 
measured a negative control and an antigen cocktail containing 5 proteins in buffer (IL-6, 
IL-1?, TNF-?, PSA, GFP) each at two concentrations and one BSA control, but spotted in 7 
replicates giving rise to 1'408 experiments. 
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Figure 2.3: Multiplexed assay and antibody cross-reactivity testing. Fluorescent signal and 
binding curves for 5 different proteins (PSA, TNF-?, IL-6, IL-1?, and GFP) quantitated in 
parallel on a single device. Concentrations for the primary and secondary antibodies used in 
this experiment were 600 nM and 6 nM, respectively. Each panel shows the signal obtained 
from the specific primary antibody to the given antigen detected with the various secondary 
fluorescently labeled detection antibodies. The results show that each antigen was specifically 
detected by the correct antibody pair and that no significant cross reactivity occurred between 
the antigens and antibodies tested in this experiment. Left y-axis: phycoerythrin labeled 
secondary antibody signal; right y-axis: Alexa Fluor 647 labeled secondary antibody signal 
(error bars are std. dev. n=7).  
?
The solutions were introduced on-chip starting with the BSA control and then from the 
lowest to the highest concentration of the antigen cocktail, one for each button. As shown in 
Figure 2.3 and Figure SI 2.2 the specific signal from each reaction is considerably higher 
than the non-specific specific signal, indicating that, at least for these antibody 
combinations, no considerable cross-reactivity was observed.  
Depending on the antigen the LOD varies from 4 pM to 30 pM. In our previous work 
[16]  LODs of 3.67 pM, 742 fM, 897 fM and 1.04 pM were achieved for TNF-?, IL-6, IL-1? 
and PSA, respectively. These LODs are comparable to other microfludic methods. Zheng et 
al. report a MITOMI device capable of detecting 10-100 pg/ml (55.6 – 556 fM) of CEA [6], 
Fan et al. report a sensitivity of <1-30 pM for various cytokines using a barcode based 
microfluidic platform [2], and Pla-Roca et al. measured LODs for TNF-? = 15.6 pg/ml (917 
??????????????????????????
???
??
???
???
???
???
??
?
???
???
???
?
??? ??? ???
???
????
????
?
??????????????
???
??
???
???
???
???
???
??? ??? ???
?
???
???
???
???
?
????
????
????
????
????
?
??????????????
??????????????????????????
???
??
???
???
???
???
???
??? ??? ???
??????????????
?
???
???
?
????
????
????
?
??????????????????????????
??? ??? ???
?
???
????
????
?
???
???
???
???
?
??????????????
???
??
???
???
???
???
??
??????????????????????????
??? ??? ???
?
???
???
???
???
???
?
????
????
????
?
??????????????
???
??
???
???
???
???
??
??????????????????????????
????????????????
?????????????????
??????????????????
???????????????????
?????????????????
??????????????
????????
??????????????????
????????
???
????
???
?????
????
Chapter 2 – A microfluidic platform for high-throughput multiplexed protein quantitation 
?20 
fM), IL-6 = 42.9 pg/ml (2.04 pM), and IL-1? = 12.3 pg/ml (683 fM) [12]. Commercially 
available macroscale assays often exhibit higher sensitivities. Meso Scale Discovery reports 
the following sensitivities: TNF-? = 1.1 pg/ml (64.7 fM), Il-6 = 0.7 pg/ml (33.3 fM), and IL-
1? = 2.4 pg/ml (133.3 fM), and Luminex: TNF-? = 25 pg/ml (1.47 pM), IL-6 = 5 pg/ml 
(238.1 fM), and IL-1? = 15 pg/ml (833.3 fM) 
2.2.4 - Combinatoric screen to identify functional antibody combinations 
Immunoassays generally require two or three antibodies, two of which directly bind to the 
biomarker of interest, while the third is required for readout. It can thus be non-trivial to 
identify combinations of antibodies that function in concert, particularly the two antibodies 
that are required to bind to the same protein biomarker. In addition to this combinatoric 
problem of identifying antibodies that work well together, it is also of interest to identify 
those antibodies that have the highest affinity for their antigen. Our multiplexed 
immunoassay platform is ideally suited to conduct large-scale screens to address these 
issues. 
To test whether our platform can be used to identify functional antibody combinations we 
chose to optimize a 3-antibody immunoassay for PSA. We acquired 4 primary biotinylated 
anti-PSA monoclonal antibodies, 4 secondary anti-PSA antibodies, and 4 tertiary anti-rabbit 
IgG antibodies labeled either with phycoerythrin or Alexa-Fluor 546 (Table 2.1), originating 
from 4 different antibody suppliers. In addition to testing all 64 antibody combinations we 
also decided to titrate the secondary antibody, to derive relative binding affinities of these 
antibodies. 
 
 
Table 2.1: List of antibodies. The table lists the 12 antibodies tested. Description, species, 
clonality, supplier and catalog number are provided for each antibody (Life-Technologies did 
not provide the clonality for antibodies ? and ? but they are likely polyclonal antibodies). The 
first set (A-D) includes the biotinylated primary antibodies, the second set (1-4) the secondary 
antibodies, and the third set (???) the tertiary antibodies conjugated with phycoerythrin or 
Alexa Fluor 546. 
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We performed the combinatoric screen in 3 different ways. In the first experiment we 
spotted the 4 secondary antibodies, each at 6 different concentrations (including a no-
antibody control), and the 4 tertiary antibodies generating 96 unique combinations (4x4x6) 
in quadruplicate requiring all 384 unit cells on the device. We then surface immobilized the 
4 biotinylated primary antibodies on the 4 MITOMI detection areas to generate 384 unique 
conditions performed in quadruplicate for a total of 1'536 assays. We then tested the 
antibody combinations for their ability to detect 100 pM of PSA (Figure 2.4). 
 
 
Figure 2.4: Screening of antibody combinations for PSA detection: secondary and 
tertiary antibodies were spotted. Different combinations of four secondary antibodies (1-4) 
and four tertiary antibodies (?? ?) were spotted. The secondary antibodies were spotted at six 
different concentrations, and the tertiary antibody at a concentration of 30 nM. After surface 
derivatization, four different primary antibodies (A-D) were flowed in sequence, one for each 
button, followed by 100 pM PSA in a buffer solution. Next the secondary antibody was 
allowed to diffuse in the reaction chamber and finally, the tertiary (???) antibodies diffused 
in reaction chamber.  
 
This experiment provided a global overview of the performance of the various antibody 
combinations, and showed that two of the secondary antibodies (#1 and #2) were non-
functional, or performed poorly. We next repeated the experiment with spotted primary and 
secondary antibodies and testing 3 of the 4 tertiary antibodies (Figure 2.5). We opted to 
remove the ? tertiary antibody from this screen as it gave consistently high non-specific 
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fluorescent background. This second screen returned qualitatively the same results as the 
first screen.  
 
Figure 2.5: Screening of antibody combinations for PSA detection: primary and 
secondary antibodies were spotted. 16 different combinations of antibodies were spotted: 
four primary antibodies (A-B) and four secondary antibodies (1-4). The secondary antibodies 
were spotted at six different concentrations (0, 0.2, 1.2, 6, 28 and 140 nM), and the primary 
antibody at a concentration of 600 nM. After the surface derivatization, the primary antibody 
was allowed to diffuse and immobilize to the surface, then 100 pM PSA was flowed in the 
chip. Next the secondary antibody was allowed to diffuse in the reaction chamber and finally, 
three different tertiary antibodies (?, ?, ?) were sequentially flowed, one for each button.  
 
We then repeated the screen on 4 separate devices by spotting 12 concentrations of the 
secondary antibody, immobilizing one of the 4 biotinylated antibodies in all four MITOMI 
detection areas, and testing each fluorescently labeled tertiary antibody on a separate 
MITOMI button for a total of 768 unique conditions (12x4x4x4) with 8 repeats gathering a 
total of 6'144 data points (Figure 2.6). 
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Figure 2.6: Combinatoric antibody screen. Four different secondary antibodies (1-4) were 
spotted at 12 different concentrations on four epoxy glass slides and aligned to PDMS chips. 
For each device one of the four primary antibodies (A-B) was flowed at a concentration of 30 
nM through the device and immobilized on the four MITOMI detection regions. Next, PSA 
was flowed at a concentration of 100 pM. Then, the secondary antibodies were allowed to 
diffuse into the reaction chamber. Finally, the four different tertiary antibodies (? - ?) were 
flowed sequentially at a concentration of 30 nM one for each MITOMI button. (error bars are 
std. dev. n=8). 
 
We found no major differences in performance between the 4 primary antibodies tested, 
but observed a considerable variation in the secondary and tertiary antibody performances. 
The secondary polyclonal antibody #1 from Fitzgerald repeatedly failed in all combinations 
tested and the two polyclonal antibodies (#3 and #4) from Abcam consistently outperformed 
the monoclonal antibody #2 from the same supplier. Both tertiary antibodies (? and ?) from 
Abcam gave non-specific signal, apparently because of poor antibody purification after 
conjugation to phycoerythrin. Nonetheless tertiary antibody ? performed exceedingly well in 
our screen, but did give rise to considerable non-specific signal when used in combination 
with primary antibody B. The second best performer of the tertiary antibodies was antibody 
? from Life-Technologies. These results show that there is a significant variability in 
antibody performance, but that it is possible to identify functional antibody combinations 
rapidly, and cost effectively on our multiplexed immunoassay platform.  
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2.2.5 - Stability test 
We envision these immunoassay devices to ultimately be used either in research or clinical 
settings, which requires that the assembled microfluidic device and reagents contained 
therein be stable for extended periods of time, preferably at ambient conditions. We 
therefore performed a stability test to determine how long the device maintained its 
functionality.  Six slides were spotted with primary and secondary antibodies against GFP. 
After bonding the PDMS device with the spotted glass slides the assembled devices were 
stored at 40°C for up to one month. We tested devices periodically after one, two, and four 
weeks under the same experimental conditions. After one week at 40°C we observed no 
significant decrease in signal from the stored chip as compared to a new device (Figure 2.7). 
After two weeks the signal decreased by ~20% and after one month the signal decrease by 
about 50%. This study indicates that assembled devices are indeed functional after 1 month 
stored at elevated temperatures and that after four weeks the decrease in signal is within 
acceptable limits. 
 
 
Figure 2.7: Stability test. (left column) Intensity of the fluorescent signal as a function of the 
GFP concentration flowed through the channel, using a new device and devices stored at 
40°C for 1, 2, and 4 weeks. (Right column) Percentage difference between the mean signals 
measured on the new device and those stored for different amounts of time. 
 
In this series of experiments we assembled the devices, stored them at elevated 
temperatures, and then performed all fluidic operations. This still requires the use of 
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biotinylated-BSA, and neutravidin. These reagents should be reasonably stable in solution or 
in lyophilized form, and thus no hindrance to applications in a variety of environments. We 
nonetheless tested whether it is possible to assemble a device, perform the surface chemistry, 
dry and store the device. The use of oil (Fluorinert FC-40) in the control layers prevented 
premature re-hydration of the spotted antibodies. We observed that the low-viscosity oil 
could slowly seep through the PDMS, leading to fouling of the flow layer and the surface 
chemistry. Storing the device in vacuum over-night eliminated this problem and allowed us 
to perform a functional immunoassay one day after generating the surface chemistry and 
drying the device. A better solution would be to remove the oil from the control lines after 
generating the surface chemistry, eliminating the need for vacuum storage. The signals 
obtained from this device were lower than from devices with a freshly prepared surface 
(Figure SI 2.3), but sufficiently high to conduct quantitative measurements. It is thus 
possible to decouple surface preparation from the actual assay with good results (LOD of 10 
pM instead of 4 pM), although the approach could be further optimized (choice of oil, 
generating a more stable surface chemistry, etc.). Nonetheless, these studies indicate that 
devices can be pre-assembled and stored, effectively decoupling chip production and 
utilization.  
?
2.3 - Conclusions 
We developed a microfluidic device able to perform multiplexed analysis of up to 384 
biomarkers in four samples for a total of 1'536 immunoassays per device. The consumption 
of antibodies is reduced to nanogram amounts, drastically decreasing assay cost. The 
primary hurdle to applying this platform to the detection of hundreds of protein biomarkers 
is the initial acquisition cost of a large number of antibody pairs, which was prohibitive for 
this proof-of-concept study. Nonetheless the drastically reduced antibody consumption of 
our platform means that once a library of antibodies is acquired it becomes a long-lasting 
resource sufficient for ~100'000 assays. Once initial antibody pairs are acquired and 
validated, they can be used for thousands of assays also eliminating problems associated 
with antibody batch-to-batch variability, which otherwise would require significant re-
validation efforts especially in clinical settings. The platform can of course be used to 
measure a smaller number of biomarkers. For example, 96 antibody pairs can be spotted in 
quadruplicate to measure 96 biomarkers in four samples with higher accuracy than could be 
achieved with a single measurement. We recently demonstrated that each MITOMI button 
can be used to analyze 3 different samples [20], which when applied to the current device 
would increase the sample throughput from 4 to 12 samples and 4'608 assays per device.  
To validate the platform, four human antigens IL-6, IL-1?, TNF-?, and PSA were 
detected achieving LODs in the range of 4-30 pM. We also applied the platform to a high-
throughput combinatoric screen to identify functional antibody combinations. We showed 
that the chip can be stored after assembly for extended periods of time in adverse conditions 
(40°C) enabling the possibility to deploy such devices as academic or clinical research tools. 
All remaining processing steps are readily automated, and the final method only requires 
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user intervention to introduce a wash solution and samples onto the device. With our current 
device the antibody derivatization steps require a significant amount of time (2-3 hours). 
These steps could be drastically accelerated by including active mixing on the device [28], 
[29]. Active mixing could reduce each step to below 10-15 minutes, allowing the entire 
assay to be performed in less than 1-2 hours. These results show that MITOMI based high-
throughput protein quantitation is an appealing approach for applications in clinical and 
basic research. Potential applications of the technology include the analysis of cellular 
signaling pathways [30] and analysis of clinical samples. A number of clinical investigations 
are currently underway with the aim to perform full genome and microbiome sequencing 
coupled to the analysis of a large number of serum proteins [31]. The technology presented 
here should be an appealing choice for the comprehensive analysis of medium to large 
panels of protein biomarkers in clinical samples, particularly since we recently demonstrated 
that a similar microfluidic platform was applicable to measuring protein biomarkers in 
clinical serum samples [16]. 
 
2.4 - Materials and methods 
2.4.1 - Device fabrication 
The device is composed of two PDMS layers (control and flow layer) aligned to an epoxy-
functionalized microscope slide. The devices were fabricated by multilayer-soft-lithography 
[18]. SU8 GM1060 photoresist was used to pattern the 30 ?m high control layer, which was 
spin coated first for 10 s at 500 rpm, then for 20.3 s at 2527 rpm, once more at 2527 rpm for 
40 s, then for 1 s at 3527 rpm, followed by 1 s at 2527 rpm. After a soft bake step the wafer 
was exposed on a MA6 mask aligner for 8 s followed by a post exposure bake. The exposed 
wafer was developed in PGMEA, followed by a hard bake at 160°C. AZ9260 photoresist 
was used for the 10 ?m high flow layer. It was spin coated for 10 s at 800 rpm, followed by 
40 s at 1800 rpm. After a soft bake the wafer was exposed on an MA6 mask aligner for two 
intervals of 18 s. The flow layer mold was annealed at 180°C for 30 minutes to round the 
flow channels. 20:1 and 5:1 ratios of elastomer (Sylgard 184) were used for the flow and the 
control layer, respectively. These were cured at 80°C for 30 minutes and then aligned. After 
aligning the flow and control layer were bonded at 80°C for 1.5 hours. 
2.4.2 - Epoxy-silane coated glass slide 
The protocol consists of two parts: cleaning of the glass slides followed by coating them 
with epoxy silane. In the first step a solution of milli-Q water and ammonia solution 
(NH4OH 25%) in a 5:1 ratio was heated to 80°C. When the solution reached said 
temperature, 150 ml of hydrogen peroxide (H2O2 30%) was added to the bath. The glass 
slides were immersed in this solution for 30 minutes. Glass slides were then rinsed with 
milli-Q water and dried with nitrogen. In the second step the slides were submerged in a 1% 
solution of 3-Glycidoxypropryl-trimethoxymethylsilane (97% pure) in toluene for 20 
minutes. The slides are then rinsed with fresh toluene to remove any unbounded 3-GPS, 
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dried with nitrogen and followed by a baking step at 120°C for 30 minutes. The glass slides 
were sonicated in fresh toluene for 20 minutes and afterwards rinsed with isopropanol and 
dried. The epoxy-coated slides were stored in a vacuum chamber at room temperature until 
used. 
2.4.3 - Microarray spotting 
A high-throughput microarray platform (Genetix QArray2) was used to array the reagents. 
Depending on the experiment a combination of primary, secondary, tertiary antibody, and 
sample were spotted. A 4.9 nL delivery-volume spotting pin  (946MP8XB, Arrayit, USA) 
was used to array all samples.  Each spot was spotted 5 times to increase reagent 
concentrations. After each sample the pin was washed 3 times using dH2O for 500 ms, 
between each washing step the pin was dried for 500 ms. The humidity in the spotting robot 
was set to 60%.  
2.4.4 - Antibodies and proteins 
Biotinylated goat polyclonal antibody to GFP was purchased from Abcam (ab6658), EGFP 
from Biovision (4999-100) and the anti Penta-His Alexa Fluor 647 conjugate was purchased 
from Qiagen (35370). A matched monoclonal anti human-PSA antibody pair and purified 
native human PSA were purchased from Fitzgerald Industries International (MA, USA) (10-
P20E, 10-P20D, 30C-CP1017U). Anti-PSA antibodies were purchased from Abcam 
(ab53774, ab76113, ab19554) and from Fitzgerald (70R-35481). Anti-PSA biotin conjugated 
antibodies were purchased from Abcam (ab182031, ab77310, ab182030) and from Abcore 
(1B-289). The anti-cytokine antibodies were purchased from eBioscience: IL-6 biotin-
conjugate, IL-1? biotin-conjugate, TNF-?, (13-7068-81, 13-7016-81, 16-7384-85). The anti 
human-IL-6 (12-7069-81), IL-1? (13-7016-81), TNF-? (12-7349-81) labeled with 
phycoerythrin (PE), human IL-6 protein standard (39-8069-65), human IL-1? protein 
standard (39-8018-65), human TNF-? protein standard (39-8329-65) were purchased from 
eBioscience. Goat anti-Rabbit IgG labelled with phycoerythrin (Pe) were purchased from 
Abcam  (ab72465, ab97070) and from Life-Technologies (P2771MP), Goat anti-Rabbit IgG 
labelled with Alexa Fluor 546 from Life-Technologies (A-11010). Neutravidin biotin-
binding protein and the biotinylated bovine serum albumin BSA were purchased from 
Thermo Scientific (29130 and 31000 respectively).  
Primary antibodies for PSA (10-P20D) and TNF-? were biotinylated using a 
ChromaLink One-Shot Antibody Biotinylation kit (Solulink) according to the manufacture 
instructions. Anti human PSA (10-P20E) was labeled with PE using the R-PE Antibody All-
in-One Conjugation kit (Solulink) according to the supplied protocol.  
2.4.5 - Device operation 
Microfluidic control channels were primed with dH2O (or oil: Fluorinert FC-40) starting at 5 
psi, once the channels were completely filled, the pressure was increased to 15 psi to close 
the fluidic valves and to 20 psi to actuate the MITOMI button membranes. All reagents were 
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aspirated into Tygon tubing (i.d. 0.51 mm, o.d. 1.52 mm) and connected to the flow 
channels, and the flow-channel pressure was set at 3.5 psi [15]. 
2.4.6 - Data analysis 
The microfluidic device was scanned using a fluorescent microarray scanner (ArrayWorx e-
Biochip Reader, Applied Precision, USA). The images were exported as 16-bit TIFF files 
and analyzed using microarray image analysis software (GenePix Pro v6.0, Molecular 
device). Non-linear regression analysis of the data was performed using Prism 5.0  
(GraphPad). 
 
2.5 - Supplementary 
2.5.1 - Representative fluorescent image of the unit cell of the multiplex 
detection 
 
 
Figure SI 2.1: Fluorescent images of some of the unit cells on the device. All combinations 
of the five different primary antibodies and secondary antibodies were tested. A negative 
control (2% BSA in PBS) and a cocktail of proteins in buffer (GFP, IL-6, IL-1b, TNF-a, and 
PSA), at three different concentrations (5, 20, 100 pM), were sequentially flowed. The color 
bars indicate the relative fluorescence intensity. 
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2.5.2 -  Multiplexed assay spotting 2 nM concentration secondary antibody 
?
?
Figure SI 2.2: Multiplexed assay and antibody cross-reactivity testing. Fluorescent signal 
and binding curves for 5 different proteins (PSA, TNF-?, IL-6, IL-1?, and GFP) quantitated 
in parallel on a single device. Concentrations for the primary and secondary antibodies used 
in this experiment were 600 nM and 6 nM, respectively. Each panel shows the signal obtained 
from the specific primary antibody to the given antigen detected with the various secondary 
fluorescently labeled detection antibodies. The results show that each antigen was specifically 
detected by the correct antibody pair and that no significant cross reactivity occurred between 
the antigens and antibodies tested in this experiment. Left y-axis: phycoerythrin labeled 
secondary antibody signal; right y-axis: Alexa Fluor 647 labeled secondary antibody signal 
(error bars are std. dev. n=7). 
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2.5.3 - Stability on the surface chemistry 
?
 
Figure SI 2.3: Stability on the surface chemistry. Fluorescent intensity as a function of GFP 
concentration 1 day after generating the surface chemistry on the device (error bars are std. 
dev., n=9). The control lines were filled with oil (Fluorinert FC-40), and the functionalization 
of the surface was performed, as described. Next, the flow layer was dried by pushing air 
through the channel at 3.5 psi for 30 minutes. The chip was then stored in a vacuum chamber 
at room temperature for 1 day. To perform the immunoassay the chambers containing the 
spotted antibodies against GFP were filled with PBS in order to re-hydrate the spots. The unit 
cells were then isolated and the primary antibody allowed to diffuse into the reaction 
chamber. After a washing step, four different concentrations of GFP were flowed in 
sequence, one for each button. Finally, the secondary antibody was allowed to diffuse into the 
reaction chamber and the device was scanned. 
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  Chapter 3
A digital-analog microfluidic platform for 
patient-centric multiplexed biomarker 
diagnostics of ultra-low volume samples 
Reprinted with permission from: Francesco Piraino*, Francesca Volpetti*, Craig Watson and 
Sebastian J. Maerkl (2016) ACS Nano vol.10 pp. 1699–1710. Copyright (2016) American 
Chemical Society. 
*Equally contributing authors 
?
Detection of biomarkers is essential for the diagnosis of diseases. The use of microfluidics 
plays a key role for the future diagnostic platforms. A powerful platform should be able to 
combine low limit of detection LOD (sub-picomolar), high dynamic range (?5 orders of 
magnitude), multiplexing capability (?4) and use low volume samples (<5 ?l). Finally the 
setup should be portable to allow its use in a resource-limited environment. 
We developed a two layers microfluidic device, composed of 16 independent assay units. 
In half of the units there are MITOMI (mechanically induced trapping of molecular 
interactions) buttons, for analog detection, and in the other half buttons patterned with 
femtowells, for digital detection. Analog detection is achieved observing the increase of 
fluorescent intensity due to the increase of concentration of the analyte. In digital-MITOMI 
the increasing analyte concentration gives rise to increasing number of positive wells. The 
combination of the two detection approaches allows achieving a broad dynamic range and 
low LODs. Single enzyme detection has been demonstrated using digital readout. 
Successively a digital immunoassay, detecting GFP in serum and in buffer, has been 
performed. The LODs achieved, with digital-analog detection, were 10 fM in buffer and 
12fM in serum with a dynamic range of 5 orders of magnitude. 
A portable and low cost microfluidic Diagnostic System (?FDS), composed of a 
microfluidic control system, a fluorescent USB microscope and a netbook, has been 
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assembled. Using the ?FDS we were able to detect human IL-6 levels in serum and achieve 
a LOD of 1 pM. We also measured levels of different species of anti IgG Ebola virus spiked 
in 5 ?l of whole blood. We conducted multiplexed assays over an IgG concentration range of 
0.1-100 nM and we obtain a LOD of 100 pM-1 nM in whole blood. 
In summary, we developed an integrated, multiplexed digital-analog device that can 
potentially be applied for point-of-care testing.  
 
3.1 - Introduction 
Management and prognosis of disease requires the measurement of biomarkers. Quantitative 
detection of low abundance biomarkers is of great interest for health monitoring and 
biological applications because protein biomarkers can be present at low concentrations of 
10-15 to 10-12M in biofluids [1]. Furthermore, detection of biomarkers in body fluids such as 
whole blood is very desirable. Next generation diagnostic platforms are eliciting 
considerable excitement as they promise a paradigmatic shift in how disease diagnosis and 
health monitoring is conducted in the near future [2].  
Biomolecular detection of proteins has been carried out using nanostructured 
microelectrodes [3], nanoparticles probes [4], nanomaterials and biomaterials in 
electrochemical arrays [5]. Microfluidics has been developed to precisely manipulate low 
sample volumes, enable large-scale integration, and improve bioassay performance [6]. 
Numerous microfluidic systems have been developed for miniaturization of immunoassays 
over the years [7]. Although the microfluidic format has enhanced the performance of 
immunoassays considerably few microfluidic assays exist that simultaneously fulfills all of 
the following performance criteria: i) low Limit Of Detection (LOD, sub-picomolar), ii) high 
dynamic range (5 orders of magnitude or better), iii) multiplexed biomarker analysis (4 or 
more), and iv) compatible with ultra-low volume (<5 ?l) samples (Table 3.2).  
A notable recent example is a platform developed by the Rusling group, which achieved 
outstanding sensitivity, high dynamic range (~5 orders of magnitude), and multiplexed 
detection of 4-6 analytes, but required dilution of samples prior to quantitation [8]. Another 
important and often overlooked aspect is the development of portable and low-cost device 
control and readout instrumentation. Another case of a multiplexed platform is the blood 
barcode chip reported by Fan et al. that achieved multiplexed protein biomarker detection 
from 10?l whole blood samples diluted to 90?l with buffer [9]. Device readout required an 
expensive research grade DNA microarray scanner restricting its use to point-of-care (POC) 
applications. A further report described a nanoplasmonic electrical field-enhanced resonating 
device (NE2RD), which achieved an impressive LOD of ~23 fM (400f g/ml) for detecting 
interferon-? in human serum and a dynamic range of 8 orders of magnitude [10]. It thus 
meets the criteria of high LOD and dynamic range, but NE2RD doesn’t support multiplexed 
analysis of biomarkers and requires a sample volume of 100 ?l per analyzed biomarker. 
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Research and clinical laboratories have extensively used Enzyme-Linked Immunosorbent 
Assays (ELISA) for protein detection. To enable the use of standard ELISA microplate 
based tests in resource-limited settings, Berg and coworkers created a hand-held cellphone-
based colorimetric microplate reader, which illuminates a 96-well plate with a light-
emitting-diode (LED) array. This LED light is transmitted through each well, and is then 
collected via 96 individual optical fibers. They tested this platform in a clinical microbiology 
laboratory using FDA-approved mumps IgG, measles IgG, and herpes simplex virus IgG 
(HSV-1 and HSV-2) ELISA tests [11]. However, the method uses standard ELISA assays 
for detection of the biomarkers, which require large sample and reagent volumes prohibiting 
multiplexed, sensitive analysis of ultra-low volume samples, and the assays require 
numerous pipetting steps. 
Digital immunoassays have emerged as a robust technology for sub-picomolar detection 
of proteins [12][16]. These assays usually use beads placed into micrometer-sized wells or 
droplets to isolate individual target molecules. Rissin et al. used microbeads coupled with 
antibodies and enzymes to detect low-abundance proteins. Their digital ELISA approach 
detected proteins in 100 ?l serum sample at concentrations as low as 0.4 fM [12]. Their 
method was then extended to simultaneously detect TNF-?, IL-6, IL-1?, and IL-1? in 
human plasma at sub-femtomolar concentrations [13]. Shim et al. reported a microfluidic 
droplet-based approach enabling single-molecule-counting immunoassay. The femtoliter 
droplets produced with their device could be used to encapsulate single biomolecular 
complexes tagged with a reporter enzyme. Their prototype system was validated by 
detection of a biomarker for prostate cancer in buffer, down to a concentration of 46 fM 
[14]. Lastly, Ge et al. showed that the concept of Brownian trapping with drift could be 
applied to improve quantitative molecular measurements. Their approach has the potential to 
combine high-sensitivity, broad dynamic range, and end-point readout. This concept was 
tested with enzyme and TNF-? measurements in a microfluidic device [15]. Although many 
of the methods reported have the ability to digitally detect biomarkers, the number of unique 
digital units that in turn defines the dynamic range often limits them. One strategy to 
improve dynamic range for digital immunoassays involves combining digital readout with 
an analog readout into a digital-analog hybrid platform as demonstrated by Rissin et al. who 
achieved a dynamic range of 4 orders of magnitude [17].  
In this paper we describe a multiplexed microfluidic platform that combines digital and 
analog detection based on mechanically induced trapping of molecular interactions 
(MITOMI) [18] to create a portable, integrated, digital-analog hybrid microfluidic device 
capable of detecting biomarkers with high-LOD and dynamic range. Our integrated 
microfluidic platform allows the multiplexed detection and quantitation of protein 
biomarkers in a 5 ?l serum or whole blood sample obtainable by a pinprick. We 
characterized our platform by performing single enzyme measurements, and digital 
immunoassays achieving single molecule detection and digital detection of 10 fM GFP in 
buffer and 12 fM GFP in human serum and a dynamic range of 5 orders of magnitude. We 
demonstrate the applicability of our platform to clinically relevant tests by performing 
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multiplexed digital detection of anti-Ebola antibodies in serum at concentrations down to 1 
pM. Finally, we combine our microfluidic device with a low-cost, portable microfluidic 
control system and a fluorescence USB microscope to enable diagnostic testing at home, or 
in resource limited field-environment in addition to clinical point-of-care settings. Using our 
portable, field-compatible hardware we demonstrate the multiplexed detection of anti-Ebola 
IgGs in an ultra-low volume whole blood sample.  
?
3.2 - Results and Discussion 
3.2.1 - Microfluidic digital-analog device 
The microfluidic device, fabricated by multilayer soft lithography [19], includes 16 
independent assay units (Figure 3.1a). The assay chambers contain a deflectable (actuated by 
means of hydraulic pressure, ?P) button membrane (analog MITOMI) in half of the assay 
units and a deflectable button membrane patterned with femtowells (digital MITOMI) in the 
other half (Figure 3.1b).  
In digital-MITOMI, increasing analyte concentrations give rise to increasing 
numbers of positive wells containing one, two, or more molecules (Figure 3.1c, top row). 
Analog detection is achieved using our MITOMI mechanism where increasing analyte 
concentration results in increasing fluorescence signal density under the MITOMI button 
(Figure 3.1c, bottom row). The combination of digital and analog detection allow to have an 
increasing in the dynamic range (Figure 3.1d). We have previously shown that highly-
multiplexed biomarker detection is possible using analog MITOMI, and that such devices 
can be pre-programmed with reagents and stored at elevated temperatures for at least 2-3 
weeks[20]. In order to reduce assay time, we now incorporated active mixing using a simple 
serpentine-shaped (S-shaped) peristaltic pump [21]. The integrated peristaltic pump permits 
complete mixing of the spotted reagents in 1 minute, as opposed to 2.5 hours required when 
solely relying on passive diffusion [20], [22], [23] (Figure 3.2c).  
Despite conventional peristaltic pump where 3 independent valves are actuated by three 
independent pressure sources, in the S-shape delay pump only one valve is actuated (Figure 
3.2a, b). A single control channel crosses the flow channel three times in a serpentine path. 
The valve is split in four parallel channels in order to address the four columns. To 
characterize the mixing time the assay chamber has been filled with DI water and the 
spotting chamber with food dye color water and the pump has been activated with a period 
of closing and opening of 60 ms. A single unit has been imaged using high speed camera, 
and the signal has been analyzed in a portion of the assay chamber (Figure 3.2c). 
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Figure 3.1: The digital-analog hybrid, multiplexed microfluidic diagnostic device. (a) 
Schematic of the device flow (blue) and control (grey) layers. The chip consists of four rows; 
each with four assay units allowing a total of 16 independent assays to be performed on each 
device. (b) Each assay unit contains two reagent chambers, an assay chamber, isolation 
valves, a peristaltic pump and a MITOMI button. Phase contrast and fluorescence images of 
the analog and the digital MITOMI buttons. Schematic cross-section of the MITOMI 
detection area: a sandwich immunoassay is performed with either fluorophore-labeled (analog 
MITOMI) or enzyme-conjugated (digital MITOMI) antibodies. (c) Increasing analyte 
concentrations lead to increasing numbers of positive femtowells in a digital measurement, 
and to increasing signal densities in analog measurements. (d) The schematic plot shows how 
a broad dynamic range can be achieved by combining digital and analog measurements in the 
hybrid device. Scale bars: 150 ?m. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
The delay response of the pressure through the control channel is used instead of the time 
sequence used in the traditional peristaltic pump [24]. Valves placed in the intersection 
between spotting and assay chamber allow to mix separately the spots on the top and bottom 
chamber using only one S-shape delay valve (Figure 3.2d). 
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Figure 3.2: Serpentine-shape (S-shape) delay peristaltic pump. (a) Schematic of the S-
shape delay peristaltic pump used in this study and magnified view of a single column. (b) 
Schematic illustrations of the difference between a conventional peristaltic pump, in which 3 
independent valves are activated in sequence, and the S-shape delay peristaltic pump, in 
which a single channel is able to perform the mixing. (c) Cy3 labeled solution mixing 
measurement at a frequency of ~ 8.3 Hz (topen = tclose = 60 ms) and P = 25 psi. (d) A schematic 
illustration of the possible flow modes. Adapted from ACS Nano vol.10 pp. 1699-1710 © 
(2016). 
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3.2.2 - Digital-MITOMI characterization  
We first tested whether it is possible to count single enzyme molecules with our digital-
MITOMI buttons[25] (Figure 3.3). We conducted our initial proof-of-concept tests with ?-
Galactosidase (?G) and Fluorescein di-?-D-galactopyranoside (FDG) in buffer.  
In order to study the kinetics of substrate turnover by single ?G molecules, an 
enzyme/substrate mixture (?G + FDG) (Figure 3.3a) was introduced on chip after surface 
derivatization. We then closed the digital MITOMI buttons and the fluorescent intensity in 
femtowells of 4 buttons (484 individual femtowells) was measured using a fluorescence 
microscope. The time elapsed between combining the enzyme-substrate solutions and 
acquiring the first image was 15 minutes and we imaged the buttons for 15 minutes with a 
frequency of 5 minutes. Wells that contained one or more active ?G molecule displayed an 
increase in fluorescence intensity. Figure 3.2b shows histograms of the substrate turnover 
rates of ?G molecules for different enzyme concentrations. The results were consistent with 
Poisson statistics (Figure SI 3.1)[25]–[27], as expected for a random distribution of 
molecules in the wells. We thus established that solution phase single enzyme counting 
could be performed on an integrated digital-MITOMI assay. 
Having successfully conducted single enzyme counting we next sought to determine 
whether it is possible to also conduct digital immunoassays with our integrated digital-
MITOMI platform. We developed a coupled analog-digital immunoassay and detected his-
tagged GFP using a surface immobilized primary goat anti-GFP antibody, an Alexa Fluor 
555 labeled mouse anti-Penta-His antibody (analog MITOMI detection), which in turn is 
detected using a ?G conjugated goat anti-mouse IgG antibody (digital and analog 
amplification detection) (Figure 3.4a). Analog MITOMI is a direct detection mechanism that 
doesn’t rely on signal amplification. In analog MITOMI a specific antibody labeled with ~1-
4 fluorophores detects an immobilized antigen. Analog MITOMI thus requires a fairly high 
density of antigens/detection antibodies on the surface in order to reach the detection limit of 
a standard epi-fluorescent microscope setup. Digital MITOMI, on the other hand, relies on 
enzyme based signal amplification and small volume traps. Here an enzyme-conjugated 
antibody binds the antigen. 
The enzyme is capable of turning over a non-fluorescent substrate to a fluorescent 
product, and does so many thousands of times, giving rise to a high level of signal 
amplification. In addition, since the product molecules are confined to a small volume they 
will reach a high concentration/density, which is readily detectable with a standard epi-
fluorescent microscope. We were able to detect as low as ~10 fM (330 fg/ml) GFP in a 
buffer solution using digital-MITOMI (calculated LOD: 2.6 fM (86 fg/ml)), which is an 
improvement of 2-3 orders of magnitude compared to detection of GFP with analog-
MITOMI (LOD: 1.7 pM (55.59 pg/ml)) (Figure 3.4b). 
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Figure 3.3: Single enzyme counting with digital-MITOMI. (a) Schematic of the ?-
Galactosidase (?G) assay in which ?G is free in solution and detected by fluorescein di-?-D-
galactopyranoside (FDG) substrate turnover to fluorescein. (b) Histograms of observed 
turnover rates for individual femtowells. The bin size for all histograms is 50 s-1. Insets show 
representative microscope images of individual digital-MITOMI buttons. Scale bar: 50 ?m. 
(c) The sum of turnover rates plotted against ?G concentration. Data represent means (n=3). 
Error bars correspond to the standard deviation of the means. The dashed red line is a linear 
fit to the data (R2=0.99). Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
Digital-MITOMI thus leads to a significant increase in LOD for microfluidic 
immunoassays. To test whether digital-MITOMI is compatible with clinical samples we 
detected GFP in human serum and were able to detect 12 fM (400 fg/ml) GFP (Figure 3.4c). 
Combining digital-MITOMI and analog-MITOMI detection on a single platform increases 
the dynamic range, in this case covering a range ~5 orders of magnitude between 10 fM (330 
fg/ml) to at least 5 nM (164 ng/ml) without requiring any sample dilutions or other 
additional on- or off-chip processing steps.  
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 Figure 3.4: Digital-MITOMI Immunoassay. (a) Schematic of the GFP sandwich assays 
performed on the microfluidic device and detected with digital-MITOMI and analog-
MITOMI. (b) Digital-MITOMI GFP immunoassay in buffer. Plotted is the sum of slopes of 
femtowells above background as a function of GFP concentration. Plotted is the intensity of 
Cy3 signal as function of GFP concentration. (c) Digital-MITOMI detection of GFP in human 
serum over concentrations ranging from 12 fM to 50 fM. Intensity of fluorescein signal is 
plotted as function of GFP concentration. Data were obtained with a research grade 
fluorescence microscope. LODs were determined from the signal of a negative control plus 3 
standard deviations. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
3.2.3 - Multiplexed digital assay in serum 
After digital detection of GFP in human serum we tested whether digital detection in human 
serum was also possible for a clinically relevant biomarker. We chose to diagnose Ebola 
virus infection by detecting the presence of anti-Ebola virus glycoprotein (GP) IgG 
antibodies [27][29]. Infectious hemorrhagic fevers caused by the Ebola virus results in 
mortality rates of up to 90% [31], and no effective vaccines or therapeutics are currently 
available. The highly infectious and lethal nature of this virus requires the development of 
novel diagnostic methods in order to monitor and control outbreaks [32], [33]. Although 
anti-Ebola IgG levels begin to rise 8-10 days after disease onset [34], detection of IgG 
antibodies does represent a viable diagnostic test for symptomatic and asymptomatic 
individuals [35], [36]. To demonstrate the multiplexing capability of the platform, we 
programmed a single device with Ebola GPs from 3 virus species (Bundibugyo, Reston, and 
Zaire) plus a negative control and performed 4 technical replicates of each on a single device 
(Figure 3.5a, b). 
 
?
??
?P
??????????????
???????????
?????????????????
???????????
?????????????????????????????????????
???
??????????????????????????????????
????????????????????????????
????????????????????????????????????????????????
?P
?????????????
? ?????? ? ???????????
?
?????
?????
?????
????????????????????????????
??????
??????
??????
??????
???
??
??
??
??
???
???
???
???
???
??
?
??
?????????
?????????????????????????? ????? ????? ???? ????
?????? ??????
??????
??????
??????
??????
???
??
??
??
??
???
???
???
???
???
??
?
?????????
??
??????????????????????????
Chapter 3 – A digital-analog microfluidic platform for patient-centric multiplexed biomarker 
diagnostics of ultra-low volume samples 
?42 
 
Figure 3.5: Multiplexed digital Ebola diagnostics in human serum. (a) Schematic of assay 
reagents allocation on the device. (b) Schematic of the assay for digital-MITOMI anti-Ebola 
virus detection. (c-e) 5pM anti-Bundibugyo Ebola GP IgG antibody, (f-h) 1pM anti-Reston 
Ebola GP IgG antibody, and (i-k) a negative control were measured on 3 independent 
devices. Shown are the signals obtained from individual femtowells (c,f,i), the sum of the 
signal in positive femtowells (d,g,j), and examples of a digital-MITOMI button for each 
sample (e,h,k). All measurements were performed in human serum. Scale bar: 700?m. 
Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
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Human sera containing 5 pM (75 pg/ml) anti-Bundibugyo GP IgG, 1pM (15 pg/ml) anti-
Reston GP IgG, and a negative control sample were measured on 3 independent chips 
(Figure 3.5c-k). For each test we analyzed the femtowells of 4 digital-MITOMI buttons of 
the corresponding capture agents (Bundibugyo GP, Reston GP, Zaire GP, and BSA). When 
the human serum sample was spiked with anti-Bundibugyo IgG a large number of 
femtowells programmed with Bundibugyo GP were positive (Figure 3.5c-e). Summing the 
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fluorescence signal of positive wells for the 3 GPs and the negative control results in a clear 
signal for Bundibugyo, low signals for Reston and Zaire, and baseline levels for the negative 
control. A similar result was obtained when testing the presence of anti-Reston GP IgG, 
which was more specific (Figure 3.5f-h). The negative control sample showed no 
appreciable signal for any of the viral species tested (Figure 3.5i-k). Digital-MITOMI thus 
provides a sensitive approach for rapid multiplexed diagnostic testing of biomarkers in 
human serum samples in a point-of-care setting. By increasing the sample flow times from 
the above used 10 minutes to 60 minutes drastically improve the observed signal for 1 pM 
anti-Reston GP IgG and allowed us to readily detect a concentration as low as 100 fM. 
3.2.4 - Portable microfluidic diagnostic system 
To enable the use of our microfluidic devices for diagnostic testing in a home-based setting, 
or in a resource-limited environment we designed and built a portable microFluidic 
Diagnostic System (?FDS). The ?FDS consists of a microfluidic control system (MCS) 
similar to a system developed by Li et al.[37], a low-cost fluorescence USB microscope, a 
netbook, and the microfluidic device (Figure 3.6). Blood sample can be picked directly from 
the finger using a micro hematocrit capillary tube (Figure 3.6a). 
 
 
Figure 3.6: Portable, low-cost ?Fluidic Diagnostics System. (a) ~5 ?l of a whole blood 
sample obtained by a pinprick is aspirated with a micro hematocrit tube and (b) transferred to 
a single use microfluidic diagnostic device. (c) Image of the ?Fluidic Diagnostic System 
consisting of a microfluidic control system, a fluorescence USB microscope, a device, and a 
netbook.  Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
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A touch screen allow to toggle each valves, the compressor and the vacuum pump. The 
interface presents 5 screen: the home screen (Figure 3.7a), one screen for switching on and 
off each solenoid valves, the compressor and the vacuum pump (Figure 3.7b), one screen for 
setting the desired pressure (Figure 3.7c), and one for selecting the routine which you want 
to run for GFP, IgE (see Appendix1) and IgG measurements (Figure 3.7d). Using 
commercially available electronic components our MCS costs 1666USD (Table 3.1). The 
fluorescence USB microscope and netbook cost 828USD and 134USD, respectively, 
bringing the hardware cost of the complete ?FDS to 2628USD. 
 
 
Figure 3.7: Graphical user interface. (a) Home screen, (b) screen for controlling each 
solenoid valves, compressor and vaccum pump, (c) screen for the pressure regulation and (d) 
the screen for the automatic routine. Adapted from ACS Nano vol.10 pp. 1699-1710 © 
(2016). 
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We tested whether we could readout our devices using a low-cost, commercially 
available fluorescence USB microscope. The lowest magnification of the USB microscope 
that allowed us to image the whole device did not permit to resolve the femtowells of our 
digital-MITOMI buttons, excluding the possibility to use digital-MITOMI. Nonetheless the 
USB microscope was able to detect GFP via analog-MITOMI, but the LOD of this approach 
was relatively poor with a LOD of 562 pM (18.37 ng/ml). In order to improve LOD we 
decided to perform a standard ELISA, using ?G and FDG turnover for signal amplification. 
Combining on-chip signal amplification with a USB microscope allowed us to detect GFP at 
concentrations as low as 5 pM (163.5 pg/ml) with a theoretical LOD of 1.9 pM (62.13 
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pg/ml). This performance is comparable to that previously achieved by analog-MITOMI and 
an expensive, research grade optical microscope [20] (Figure 3.8b). 
  
 
Figure 3.8: GFP analog-amp and analog MITOMI assay. (a) Schematic of the GFP 
sandwich assays performed on the microfluidic device and detected with analog 
amplification, and analog-MITOMI. (b) Detection of GFP in 2% BSA PBS buffer solution 
with concentrations ranging from 500 fM to 5 nM. Analog amplification and analog MITOMI 
detection of GFP. Data were obtained with a fluorescence USB microscope. LODs were 
determined from the signal of a negative control plus 3 standard deviations. (c) 
Representative fluorescence images of one assay unit taken with the USB microscope for 
different concentrations of GFP in 2% BSA PBS using the analog amplification method. 
Scale bar: 350 ?m. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
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We also detected human IL-6 in human serum with the same approach. Biotinylated 
primary antibody and secondary antibody against human IL-6 were spotted on the glass 
slide. The human serum was spiked with human IL-6, four different concentrations were 
sampled in 4 independent microfluidic chips.  After the secondary antibody was pumped in 
the chamber the tertiary antibady ?-galactosidase labeled was flowed through the channels. 
The signal from the turn over of the FDG has been measured using the USB microscope. 
The LOD (1 pM (21 pg/ml), (Figure 3.9) was also comparable to results previously achieved 
by analog/MITOMI and a research grade optical microscope [20].Serum levels of IL-6 in 
patients with oral cancer are 20 pg/ml, while healthy persons are below 6 pg/ml [38], [39].  
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Figure 3.9: IL-6 detection (a) Schematic of the IL-6 sandwich assays performed on the 
microfluidic device and detected with analog amplification. (b) Detection of IL-6 in human 
serum with concentrations ranging from 100 pM to 1 pM. Data were obtained with a 
fluorescence USB microscope. LODs were determined from the signal of a negative control 
plus 3 standard deviations. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
3.2.5 - Multiplexd Ebola diagnostic in whole blood sample 
To test whether our platform could be used to detect Ebola specific IgG levels in a resource-
limited setting we measured anti-Ebola IgG antibodies spiked into whole blood samples and 
used our ?FDS for device readout. The average quantitative load of specific IgG molecules 
during a viral infection ranges from 6.6 nM-6.6 ?M (1-1000 ?g/ml) [40], [41], which defines 
the concentration range that our platform needs to be able to detect. 
Sample volumes for our device can be as small as 5 ?l of whole blood obtainable by a 
pinprick (Figure 3.1a). The blood sample is aspirated and transferred to the device by means 
of a micro hematocrit tube (Figure 3.1b). To introduce the sample onto the device we 
employ vacuum based loading, by applying vacuum to the outlet of the device and drawing 
the blood sample into and through the microfluidic device. We found that we could load a 
whole blood sample directly onto the device and perform on-chip biomarker quantitation 
without requiring any sample-pretreatment or removal of hematocytes. Previously, 
microfluidic approaches generally relied on off-chip hematocyte removal or integrated on-
chip separation approaches [42], [43], which complicated chip design and assay 
implementation. Here we show that cell-separation [44], [45][46] is not necessary in turn 
simplifying the assay and enabling multiplexed biomarker detection from an ultra-low 
volume whole blood sample. 
We conducted multiple measurements (1 experiment per concentration for a total 10 
independent experiments) over an IgG concentration range of 0.1-100 nM for the three 
Ebola species, Bundibugyo, Reston, and Zaire (Figure 3.10a-d). Using analog-MITOMI we 
were able to detect IgG antibodies specific to all three species at levels of 100 nM, with the 
exception of anti-Zaire IgG, which could be detected to a concentration of 1 nM. Employing 
on-chip enzymatic signal amplification improved the detection limit for all species to 10 nM 
and 0.1 nM for Zaire.  
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?
Figure 3.10: Multiplexed Ebola diagnostics in whole blood using the ?FDS. (a) Schematic 
of the assay for anti-Ebola virus detection in a whole blood sample. Data for different 
concentrations of (b) anti-Zaire Ebola GP IgG antibody, (c) anti-Bundibugyo Ebola GP IgG 
antibody, and (d) anti-Reston Ebola GP IgG antibody spiked in whole blood. Zaire, 
Bundibugyo and Reston glycoproteins are spotted in quadruplicate to yield two repetitions for 
the analog and the analog amplification detection mechanisms. Goat anti-rabbit IgG PE 
conjugated antibody and goat anti-rabbit IgG ?-Galactosidase conjugated antibody were 
spotted in the top and bottom part of the chip, respectively, to allow the use of both detection 
methods on the same device. Data represent means (n=2). Error bars correspond to the 
standard deviation of the means. (e-f) Representative fluorescent images of 10 nM anti-Zaire 
Ebola GP IgG antibody spiked in whole blood. (e) The analog-MITOMI signal imaged using 
a fluorescence USB microscope with a 570 nm emission filter. (f) Amplified analog signal 
detected with a fluorescence USB microscope using a 510 nm emission filter. Scale bar: 350 
?m. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
?
Actual micrographs obtained with the fluorescence USB microscope for 10 nM anti-Zaire 
Ebola IgG are shown for the analog-MITOMI (Figure 3.10e) and the analog amplification 
based method (Figure 3.10f). A dynamic range of 3 orders of magnitude can be achieved in 
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the range of 100 pM (0.15 ?g/ml) to 100 nM (150 ?g/ml) in unprocessed whole blood using 
a USB microscope, which effectively covers the clinically relevant range.  
?
3.3 - Conclusions 
Here we described the development of an integrated digital-analog microfluidic diagnostic 
platform capable of performing multiplexed detection of ultra-low volume human serum 
samples. Digital MITOMI improved the limit of detection by 3 orders of magnitude to ~10-
12 fM, compared to previous MITOMI based immunoassays, which is a significant 
improvement and will further enhance the plethora of assays MITOMI has thus far been 
applied to including Protein-DNA, Protein-Protein, Protein-RNA, and immunoassay based 
measurements [18]. By combining digital-MITOMI with standard analog-MITOMI on the 
same device we increase the dynamic range of our measurement reaching 5 orders of 
magnitude in this study. Importantly, these levels of LOD and dynamic range can be 
achieved for a multiplexed analysis of a single, ultra-low volume (~5 ?l) serum sample. 
We also developed a (Do-It-Yourself) DIY microfluidic control system, which can be 
assembled by a master student from commercially available components. The current cost of 
the MCS is 1666 USD, which could be further reduced to 1145 USD by eliminating the 
expensive pressure regulators and touch display. For device readout we demonstrate that a 
low-cost USB fluorescence microscope provides sufficient resolution to quantitate 
microfluidic diagnostic tests based on fluorescence readout.  
We have recently shown that MITOMI devices can be pre-programmed with antibody 
reagents and consequently stored at elevated temperatures of 40°C for at least 2 weeks 
without loss of function [20], making the microfluidic device itself a self-contained reagent 
reservoir with a good shelf-life. Long-term storage of enzyme-based reagents has also been 
shown previously [54]. We achieved similar sensitivities with the ?FDS as with expensive 
research grade fluorescence microscope and we showed that we could detect IgG antibody 
levels down to 100 pM in a 5 ?l whole blood sample that can be obtained by a simple 
pinprick.  
In summary, we present an integrated, multiplexed digital-analog microfluidic diagnostic 
platform with novel performance characteristics that can potentially be applied to 
measurements in clinical point-of-care settings. We also demonstrate that the same device 
can be controlled and interrogated with low-cost off-the-shelf hardware, making it a viable 
diagnostic test in home-based, field-based, or resource-limited settings. The platform is 
applicable to any protein biomarker or molecule that can be detected via an immunoassay 
based affinity reagent, which encompasses an extremely broad range of possible tests that 
the platform can perform. Our platform thus represents a basis for developing new assays to 
meet the increasing demand for on-site clinical diagnostic testing, companion diagnostics, 
generic health monitoring, as well as applications in biodefense. 
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3.4 - Methods 
3.4.1 - Reagents, antibodies, proteins, and clinical samples 
Chlorotrimethylsilane (92360), 2-propanol (IPA) (I9516), ?-Galactosidase from Escherichia 
coli (?G) (G3153), phosphate buffered saline (PBS) (P5244), ?-mercaptoethanol (P6250), 
bovine serum albumin (BSA) (A3912), Tween 20 (P1379) and human serum (H4522) were 
purchased from Sigma-Aldrich. Fluorescein di-?-D-galactopyranoside (FDG) (F-1179) and 
goat anti-rabbit IgG PE conjugate (P-2771MP) were bought from Life Technologies. Goat 
anti-GFP antibody biotin conjugate (ab6658), goat anti-human IgG Fc (SureLight® PE) 
(ab131612), anti-IL-6 (ab6672), goat anti-rabbit IgG ?G conjugate (ab136774), and rabbit 
anti-goat IgG ?G conjugate (ab136712) were obtained from Abcam. Rabbit anti-Bundibugyo 
Ebola virus glycoprotein IgG (BVGP41-A), rabbit anti-Reston Ebola virus glycoprotein 
peptide IgG (RVGP31-A), recombinant Bundibugyo-Ebola virus glycoprotein (BVGP45-R-
10) and recombinant Reston-Ebola virus glycoprotein (RVGP35-R-10) were acquired from 
Alpha Diagnostics. Anti-human IL-6 biotin conjugate (13-7068-81) and human IL-6 (39-
8069-65) were purchased from Affymetrix eBioscience. Biotinylated BSA (29130), and 
neutravidin (31000) were purchased from Thermo Fisher Scientific. Mouse anti-Penta·His 
biotin conjugate (34440) and Mouse anti-Penta·His Alexa Fluor 555 conjugate (35310) were 
purchased from Qiagen. Rabbit anti-Ebola virus GP (1501003) and recombinant Ebola virus 
glycoprotein (0501-015) were purchased from IBT Bioservices. Goat anti-mouse IgG ?G 
conjugate (401607) was bought from Merck Millipore and Enhanced Green Fluorescent 
Protein (EGFP) (4999100) from BioVision. Biotinylated natural Ara h2 (BI-AH2-1), 
recombinant Fel d1 (LTR-FD1D-1), and recombinant Der p2 (RE-DP2A-1) were purchased 
from INDOOR biotechnologies. Human clinical samples were purchased from PlasmaLab 
International. Micro hematocrit capillary tubes (7493 11) were purchased from VWR 
International.  
3.4.2 - Blood specimens 
Animals and their care were handled in compliance with institutional guidelines as defined 
in international laws and policies (EEC Council Directive 86/609, OJ L 358. 1, December 
12, 1987 Standards for the Care and Use of Laboratory Animals - UCLA, US National 
Research Council, Statement of Compliance A5023-01, November 6, 1998). 
3.4.3 - Microfabrication 
The microfluidic device consists of a flow and a control layer. Molds for each layer were 
fabricated using standard lithography techniques on 4” silicon wafers. After exposure to O2 
plasma the control layer mold was patterned with GM1050 SU-8 photoresist (Gersteltec 
Sarl, Switzerland) to a height of 30 ?m.  The mold for the fluidic layer was fabricated by a 
three-step lithography process. Briefly, a micropost array (patterned to a height of 5 ?m 
using GM1040 SU8 (Gersteltec Sarl, Switzerland)) was patterned on top of a ~10 ?m high 
SU8 layer. Then, ~15 ?m high channel features were patterned with AZ9260 photoresist 
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(Gersteltec Sarl, Switzerland). Devices were cast in polydimethylsiloxane (PDMS) using 
multilayer soft lithography.6 PDMS was prepared at a 20:1 ratio and spin-coated on the flow  
layer mold at 1900 rpm. PDMS at a 5:1 ratio was cast on the control layer mold to a 
thickness of ~4 mm. Both layers were baked at 80°C for 30 minutes. The control layer was 
peeled off from its mold and manually aligned to the flow layer mold, followed by a baking 
step at 80°C for 90 minutes. The femtowells for digital-MITOMI were 5 ?m wide and 5 ?m 
tall, giving a volume of 100 fl, with a pitch of 10 ?m. 
3.4.4 -  MicroFluidic Diagnostic System 
The system consists of an electronic printed circuit board (PCB, designed in Altium and 
printed by Euro Circuits) coupled with an Arduino (Arduino Mega 2560 R3, Distrelec), two 
pressure controllers (990-005103-015, Parker), an air pump (TM40a, TOPSFLO), a vacuum 
pump (E163-11-120, Parker), a touch screen (uLCD-43DT, 4D Systems), a pneumatic 
control subsystem (S14-2936, Pneumadyne), and a PDMS device. The cost of each part of 
microfluidic diagnostic system is listed in Table 3.1. 
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 Table 3.1: Cost table of ?Fluidic Diagnostic System. 
 
 
 
 
 
Part description Vendor Part no. 
Unit 
price 
(USD) 
Quantity 
Total 
(USD) 
      
6 valve manifold Pneumadyne S14-2936 174.35 4 697.40 
      
Vacuum pump Parker E163-11-120 68.57 1 68.57 
Air pump Amazon  TM40-A 66.35 1 66.35 
      
Electronic P controllers Parker 990-005103-015 185.71 2 371.41 
      
      
Arduino Mega 2560 Amazon 642819 37.76 1 37.76 
Printed Circuit Board Euro Circuits Custom 65.09 1 65.09 
      
Locking male header, 2-pin Digi-Key A1921-ND 0.12 2 0.24 
Locking male header, 4-pin Digi-Key A19431-ND 0.18 4 0.72 
Header pins  Digi-Key S1012E-36-ND 1.61 2 3.22 
Capacitors Digi-Key 399-10449-1-ND 0.39 4 1.55 
Diodes Digi-Key 641-1017-1-ND 0.28 2 0.56 
Power jack 2.1mm Digi-Key CP-002A-ND 0.96 1 0.96 
Resistors Digi-Key P1.0KJCT-ND 0.10 4 0.40 
DC/DC converter 5V out Digi-Key 945-1395-5-ND 9.03 1 9.03 
DC/DC converter 12V/3A 
out 
Digi-Key 945-1729-5-ND 24.54 1 24.54 
Transistor arrays 
(ULN2803) 
Digi-Key 296-15777-2-ND 0.99 3 2.97 
Transistors (for 
compressors) 
Digi-Key Z3099-ND 12.67 2 25.34 
      
4.3" LCD module w/ Res 
Touch 
Mouser uLCD-43PT 150.18 1 150.18 
      
Rechargeable Battery BixPower Bat-MP100-24V
  
139.95 1 139.95 
     -------------- 
 
Microfluidic Control 
System 
    1666.24 
      
USB microscope VWR 
International 
AM4113T-FBW 827.84 1 827.84 
      
Netbook Amazon n/a 134.31 1 134.31 
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3.4.5 - Device function and operation 
Control lines on the device were primed with Phosphate Buffered Saline (PBS) at 5 psi. 
When the control lines were fully primed the pressure was increased to 25 psi. Flow lines 
were operated at 3 psi. For the initial surface derivatization steps the neck valves remained 
closed to avoid liquid from entering the chambers containing the spotted reagents. First, the 
surface area was derivatized by flowing a solution of either biotinylated BSA resuspended to 
2mg/ml in H2O resuspended to 1 mg/ml in H2O for 10 minutes, followed by a 5 minutes 
0.005% Tween 20 in PBS. Next a 500 ?g/ml neutravidin solution in PBS was flown for 10 
minutes, followed by a 5 minutes 0.005% Tween 20 in PBS wash. The buttons were closed 
and all remaining accessible surface area was passivated with the same biotinylated solution 
as above for 10 minutes, followed by a 5 minutes 0.005% Tween 20 in PBS wash.  
To perform resuspension and mixing of the spotted reagents and the assay chamber we 
first closed valve 2 (Figure SI 3.3), in order to isolate each unit, followed by opening valves 
3 and 4, to allow mixing between the top spotting chamber and the assay chamber. Then the 
MITOMI button was opened and the pump activated. Once the mixing was completed, 
button and valves 3 and 4 were closed sequentially. The same procedure was followed for 
mixing the bottom chamber, using valves 5 and 6 instead of 3 and 4 (Figure 3.2). 
3.4.6 - Digital enzyme measurements 
After surface derivatization various concentrations of ?G ranging from 0.05 pM (0.02 ng/ml) 
to 50 pM (23.26 ng/ml) and 50 ?M of FDG were mixed and then flowed through the device. 
FDG was resuspended in a 100mM phosphate buffer, including 1mM MgCl2 and 50 ?M ?-
mercaptoethanol. As a final step, the MITOMI buttons were actuated at 25 psi. Bright field 
and fluorescent images were taken 15 minutes after the closure of the buttons with an 
exposure time of 2000 ms. To establish a calibration curve with known ?G we summed the 
observed rates of all wells above a threshold defined by the negative control and plotted the 
sum of rates versus ?G concentration. 
3.4.7 - Microfluidic digital and analog immunoassay  
For the GFP immunoassay 15 ?l of each reagent were loaded into tygon tubing, connected to 
the device and flowed in sequence at 3 psi. After surface functionalization, a 66.7 nM 
(10?g/ml) biotinylated goat anti-GFP solution in 2% BSA was flowed for 10 minutes and 
immobilized in the button region coated with neutravidin. To generate the standard curves, 
various concentrations of GFP ranging from 5 fM (0.17 pg/ml) to 5 nM (166.67 pg/ml) in 
2% BSA, and 12 fM (0.4 pg/ml) to 50 fM (1.67 pg/ml) in human serum were flowed through 
the device for 10 minutes. Next, a 13 nM (2 ?g/ml) mouse anti-Penta·His Alexa Fluor 555 
conjugate solution in 2% BSA was flowed for 10 minutes. After, a 100 pM (0.015 ?g/ml) 
goat anti-mouse IgG ?G conjugate solution in 2% BSA was flowed for 8 minutes. The 
channels were washed with 0.005% Tween PBS flowed immediately after each reagent for 5 
minutes. After the last washing step 50 ?M FDG was flowed for 4 minutes and buttons 
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closed with 25 psi pressure. Bright field and fluorescent images were taken 15 minutes after 
the closure of the buttons with an exposure time of 2000 ms.  
3.4.8 - Multiplexed digital detection of anti-EBOLA antibodies in human serum  
The recombinant virus antigens, along with the detection antibodies, were printed in a 4x4 
format on epoxy slides. Briefly, we spotted 3 different Ebola virus GPs and a BSA negative 
control in all upper spotting chambers of the unit. Goat anti-rabbit IgG ?G conjugated 
antibodies were printed in the lower spotting chamber of the unit cells. 
After surface functionalization, 15 ?l of each reagent were loaded into individual tygon 
tubings, connected to the device and flowed sequentially at 3psi for 10 minutes. First, a 7 
nM (0.45 ?g/ml) biotinylated mouse anti-Penta·His solution in 2% BSA was flowed and 
immobilized in the button region coated with neutravidin. Then, 1.9 ?M (136.8 ?g/ml) of 
recombinant Reston GP, 1.9 ?M (187.7 ?g/ml) of recombinant Bundibugyo GP, and 1 ?M 
(73 ?g/ml) of recombinant Zaire GP were pumped for 10 minutes. 5 pM (75 pg/ml) of rabbit 
anti-Bundibugyo and 1 pM (15 pg/ml) of rabbit anti-Reston in human serum were flowed for 
8 minutes (one species per chip). Next, a 100 pM (15 ng/ml) goat anti-rabbit ?G antibody 
2% BSA was pumped for 10 minutes. The channels were washed with 0.005% Tween 20 in 
PBS flowed after each reagent for 5 minutes. After the last wash step 50 ?M FDG was 
flowed for 4 minutes and buttons were closed with 25 psi pressure. Bright field and 
fluorescent images were taken 15 minutes after the closure of the buttons with an exposure 
time of 2000 ms.  
3.4.9 - Detection of human IL-6 in human serum  
Biotinylated primary antibody and secondary antibody against human IL-6 were spotted on 
epoxy slide.  
After surface functionalization, 15 ?l of each reagent were loaded into individual tygon 
tubing, connected to the device and flowed sequentially at 3psi for 10 minutes. First, 300 nM 
(43mg/ml) of primary antibody was pumped for 10 minutes and immobilized in the button 
region coated with neutravidin. Then, 1 pM (21 pg/ml), 10 pM (210 pg/ml) and 100 pM (2.1 
ng/ml) of human IL-6 were spiked in human serum, was flowed in the chip. Next, secondary 
rabbit anti human IL-6 antibody (diluted 1:500 in 2% BSA in PBS) was pumped for 10 min. 
A 100 pM (15 ng/ml) goat anti-rabbit ?G antibody was flowed for 10 min. The channels 
were washed with 0.005% Tween 20 in PBS flowed after each reagent for 5 minutes. At the 
end 50 ?M FDG was flowed for 4 minutes. Fluorescent images were taken using USB 
fluorescence microscope with the following exposure setting: Lowest, Luma 240. 
 
3.4.10 - Multiplexed detection of anti-Ebola IgG in whole blood 
In the multiplexed Ebola immunoassay we spotted 3 different Ebola virus GPs and a BSA 
negative control in the upper spotting chambers (Figure SI 3.3a i) of the unit cells. 
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Secondary antibodies were printed in the bottom spotting chambers (Figure SI 3.3a ii) of the 
units. PE conjugated antibodies were spotted in the top half of the chip, to allow analog 
detection while ?G conjugated antibodies where spotted in the bottom half of the chip to 
allow analog-amp detection. After surface functionalization, 15 ?l of each reagent were 
loaded into tygon tubing, connected to the device and flowed sequentially at 3 psi for 10 
minutes. First, a 7 nM (0.45 ?g/ml) biotinylated mouse anti-Penta·His solution in 2% BSA 
were immobilized in the button region coated with neutravidin. Then, 1.9 ?M (136.8 ?g/ml) 
of recombinant Reston GP, 1.9 ?M (187.7 ?g/ml) of recombinant Bundibugyo GP, and 1 
?M (73 ?g/ml) of recombinant Zaire GP were pumped for 10 minutes. To generate the 
standard curves, different concentrations, ranging from 0.1 nM (0.15 ?g/ml) to 100 nM (150 
?g/ml), of anti-Bundibugyo, anti-Reston, and anti-Zaire were spiked in mouse whole blood. 
A final volume of 3.5 ?l was then flown through the device from a hematocrit tube that in 
turn was plugged into the device. The mouse whole blood sample from the hematocrit tube 
was loaded into the device by vacuum suction (8 minutes at – 2.5 psi) as opposed to pressure 
driven flow. Next, 30 nM (11.7 ?g/ml) goat anti-rabbit IgG PE conjugated antibody and 2 
nM (0.3 ?g/ml) of goat anti-rabbit ?G antibody in 2% BSA were pumped for 10 minutes in 
the upper and lower half of the device, respectively. The channels were washed with 0.005% 
Tween 20 in PBS immediately after each reagent for 5 minutes. After the last washing step 
50 ?M FDG was flowed and buttons immediately closed with 25 psi pressure. Bright field 
and fluorescent images were taken with the USB fluorescence microscope 15 minutes after 
the closure of the buttons with the following exposure settings: Lowest, Luma 240. 
3.4.11 - Image acquisition, quantification and data analysis  
Pumping and mixing sequences were recorded with a Hamamatsu ORCA-Flash4.0 camera 
(C11440). Mixing time was determined by analyzing fluorescent intensity changes over time 
in a portion of the microfluidic channel during pumping (ImageJ, plugins stacks ? Measure 
hyperstack) (Figure 3.2c). The sandwich valve was closed and a Cy3 labeled solution was 
pumped in the assay chamber containing buffer. 
Fluorescent images were obtained Nikon ECLIPSE Ti microscope equipped with 
LED Fluorescent Excitation System, Cy3 and FITC filter sets, and a Hamamatsu ORCA-
Flash4.0 camera (C11440). Images were taken with a 40x objective lens (Nikon, SPlan 
Fluor, ELWD 40x/0.60, ?/0.2, WD 3.6-2.8). Alternatively, fluorescent images were taken 
with a Cy3 (AM4113T-YFBW) or FITC (AM4113T-GFBW) Dino-Lite USB fluorescence 
microscopes. 
The resulting TIFF-images were analyzed with a microarray image analysis software 
(GenePix Pro v6.0, Molecular Devices), ImageJ, Fiji or Matlab (Mathworks). Averages, SDs 
and linear fits were calculated with Microsoft Excel. Vertical scatterplots, histograms and 
statistical analysis were created and performed in Prism (Prism v5.0, Graphpad). 
?  
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3.5 - Supplementary 
3.5.1 - Single enzyme counting and activity traces 
?
 
Figure SI 3.1: Activity traces and observed turnover rates of enzymes for the ?G assay.  
Activity traces of enzymes for the ?G assay. Turnover rates are determined by linear 
regression fitting (solid red lines) to the fluorescence trajectories after background 
subtraction. Histograms of observed turnover rates for individual femtowells. The numbers of 
wells are plotted versus the increase in observed rate. For 0.5, 5, and 25 pM the peaks were 
fitted with a sum of Gaussians. The values displayed above each peak are the centers of these 
Gaussians. The inserts show the probability distribution. The black bars represent the 
experimentally obtained probability distributions calculated from the Gaussian fits. Red data 
points represent the values obtained from the Poisson distribution f(k;?)=?k e-k/k! with the 
parameter ? equal to the expected number of enzymes per chamber for 0.5, 5, and 25 pM of 
?G. Blue data points are the values obtained from the Poisson distribution for 12.5 pM of ?G.  
The bin size for all histograms is 50 s-1. Adapted from ACS Nano vol.10 pp. 1699-1710 © 
(2016). 
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3.5.2 - Microfluidic control system 
?
?
Figure SI 3.2: 3D rendering, of the MSC. 3D rendering of the MSC showing how the 
different components were arranged. Adapted from ACS Nano vol.10 pp. 1699-1710 © 
(2016). 
?  
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3.5.3 - Microfabricated diagnostic design 
?
?
Figure SI 3.3: Microfabricated diagnostic devices used in this study. (a) Design schematic 
of the analog MITOMI microfluidic device showing flow (blue) and control (grey) layers. 
The device has four rows; each row contains four unit cells for a total of 16 analog assay 
units. Each assay unit (inset) contains: a MITOMI button valve (1), a sandwich valve (2), two 
neck valves (3, 4) for the top chamber (i) and two (5, 6) for the bottom one (ii), and a 
peristaltic pump (8). (b) Digital MITOMI device. (c) Digital-analog hybrid MITOMI device, 
with 8 digital and 8 analog units. Adapted from ACS Nano vol.10 pp. 1699-1710 © (2016). 
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3.5.4 - Platform technologies for biomarker diagnostic 
?
? Digital Analog Limit of detection Dynamic range 
[order of 
magnitude] 
Sample 
volume 
[?l] 
Dilution 
required 
Multiplexing 
[units] 
This study ? ? ~330fg/ml 5 5 - 16 
Wu et al.1 ? x 1fg/ml-
0.09pg/ml 
>4 100 1:4 10 
Rissin et al.2 ? x ~6-10fg/ml 4 100 1:4 2 
Rissin et al.3 ? x 3fg/ml 4 100 - 4 
        
Inci et al.4 x ? 400 fg/ml 8 ?100 1:10 - 
Fan et al.5 x ? 17.5 pg/ml 4 10 1:10 12 
Kadimisetty 
et al.6 
x ? 10-100 
fg/ml 
5 5-10 1:30-500 6 
Krause et al.7 x P 10-40fg/ml 3 5 1:30 4 
Table 3.2: Comparison of the ?FDS with the microfluidic platform technologies for 
biomarker diagnostics. 
?
3.5.5 - Digital-MITOMI immunoassay steps 
?
 Reagent time (min) 
1 BSA (Biotinylated) 10 
2 PBS-tween  5 
3 Neutravidin 10 
4 PBS-tween  5 
5 BSA (Biotinylated) 10 
  6 PBS-tween  5 
7 Goat anti-GFP (Biotinylated) 10 
8 PBS-tween  5 
9 GFP 10 
10 PBS-tween  5 
11 Mouse anti-Penta His (Alexa Fluor 555 conjugate)  8 
12 PBS-tween  5 
13 Goat anti-mouse IgG (bG conjugate) 10 
14 PBS-tween  5 
15 FDG  4 
Table 3.3: Liquid handling sequence for the digital-MITOMI immunoassay 
?
?
?
?
?
?
?
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3.5.6 - IL-6 immunoassay steps 
?
 Reagent time (min) 
1 BSA (Biotinylated) 10 
2 PBS-tween  5 
3 Neutravidin 10 
4 PBS-tween  5 
5 BSA (Biotinylated) 10 
  6 PBS-tween  5 
7 Anti-Human IL-6 (Biotinylated) 10 
8 PBS-tween  5 
9 Human IL-6 10 
10 PBS-tween  5 
11 Rabbit anti-Human IL-6  8 
12 PBS-tween  5 
13 Goat anti-rabbit IgG (bG conjugate) 10 
14 PBS-tween  5 
15 FDG  4 
Table 3.4: Liquid handling sequence for the analog-amp IL-6 MITOMI immunoassay 
?
3.5.7 - Multiplex Ebola immunoassay steps 
?
 Reagent time (min) 
1 BSA (Biotinylated) 10 
2 PBS-tween  5 
3 Neutravidin 10 
4 PBS-tween  5 
5 BSA (Biotinylated) 10 
  6 PBS-tween  5 
7 Mouse anti-Penta His (Biotinylated) 10 
8 PBS-tween  5 
9 Pumping GP 10 
10 PBS-tween  5 
11 Sample  8 
12 PBS-tween  5 
13 Pumping secondary antibody 10 
14 PBS-tween  5 
15 FDG  4 
Table 3.5: Liquid handling sequence for the multiplex MITOMI immunoassay 
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?
Synthetically engineered cells are powerful and potentially useful biosensors, but it remains 
difficult to deploy such systems due to practical difficulties and biosafety concerns. To 
overcome these hurdles, we developed a microfluidic device that serves as an interface 
between an engineered cellular system, environment, and user. We created a biodisplay 
consisting of 768 individually programmable biopixels and demonstrated that it can perform 
multiplexed, continuous environmental monitoring. The biodisplay detected 10 ?g/l sodium-
arsenite in tap water using a research grade fluorescent microscope, and reported arsenic 
contamination down to 20 ?g/l with an easy to interpret “skull and crossbones” symbol 
detectable with a low-cost USB microscope or by eye. The biodisplay was designed to 
prevent release of chemical or biological material to avoid environmental contamination. 
The microfluidic biodisplay thus provides a practical solution for the deployment and 
application of engineered cellular systems.  
?
4.1 - Introduction 
With the advent of synthetic biology, a number of biological sensors have been engineered 
that are capable of monitoring the environment [1], [2]. Although such synthetic biological 
systems are in principle extremely powerful sensors and information processing units, they 
often lack direct applicability because suitable interfaces between the environment, the user 
and the engineered biological system don’t exist [3], [4]. The lack of such interfaces results 
in problems related to safely deploying genetically modified organisms (GMOs), while 
making it possible for them to interact with the environment and user [5]. Aside from safety 
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concerns, interfaces can solve practical problems such as keeping the engineered biological 
system alive for extended periods of time, automatic and frequent sampling of the 
environment, and facilitating readout. 
Microfluidics originated as a tool to enable analytical measurements in chemistry and 
biology [6]. In the last decades, microfluidic devices have found a plethora of applications in 
biology spanning high-throughput screening [7], cell-based assays [8], [9], and molecular 
diagnostics [10]. The use of microfluidic devices increases throughput, reduces cost, and can 
enable novel measurements [11]. In most instances the purpose of microfluidics is to enable 
or conduct analytical measurements of molecules or cells. Few examples depart from this 
dogmatic application of microfluidics and instead employ microfluidic devices as soft robots 
capable of movement and camouflage [12], or as microfluidic games [13]. One recent 
example demonstrated how engineered biological systems can be deployed by combining 
bacterial sensors with passive microfluidic channels in a wearable hydrogel-elastomer hybrid 
device capable of sensing and reporting the presence of Diacetylphlorogluicinol (DAPG), 
Isopropyl b-D-1thiogalactopyranoside (IPTG), Acyl homoserine lactones (AHL) and 
Rhamnose [14]. 
We have previously developed a method to culture and interrogate 1'152 S. cerevisiae 
strains on a microfluidic device. Each strain is cultured in a dedicated micro-chemostat and 
is interrogated optically to provide single-cell, phenotypic information on each strain. We 
applied this platform to the comprehensive, single-cell analysis of yeast proteome dynamics 
[15] and to the detailed characterization and modeling of transcriptional regulation in yeast 
[16]. Here we show that this approach can be used to generate a bacterial biodisplay. Unlike 
previous bacterial biodisplays [17], each of the 768 pixels can be independently programmed 
with a specific bacterial strain or clone. Once programmed, the device cultures cells for 
extended periods of time, while preventing contamination of the environment by GMOs 
contained on the device. We used the biodisplay to characterize the response of several 
engineered bacterial strains to small molecule analytes for extende period of time. To 
demonstrate environmental monitoring, we programmed the biodisplay with a “skull and 
crossbones” symbol using a bacterial arsenic sensor strain. The symbol is displayed when 
arsenic contaminated water is sensed by the biodisplay. We also demonstrate a multiplexed 
biodisplay that reports on the presence or absence of two small molecules: arabinose and 
arsenic. The use of an easy-to-interpret symbolic display drastically simplifies analysis, and 
is readily understood by a layman without any special hardware or analysis requirements. To 
enable field-deployment of our biodisplay we show that readout can be conducted using an 
off-the-shelf low-cost USB microscope, a cellphone, or direct visual inspection. Finally, to 
increase shelf-life and facilitate shipping / deployment of the biodisplay we programmed the 
device with B. subtilis spores, which allowed storage of the display at 80ºC for 1 month 
without any detectable decrease in viability or sensing functionality. 
?
Chapter 4 – A microfluidic biodisplay 
? 65 
4.2 - Results and Discussion 
4.2.1 - Biodisplay programming, culturing, sampling and readout 
The biodisplay has a resolution of 48 x 16 for a total of 768 programmable pixels with a 
density of 64 pixels per inch (PPI) (Figure 4.1a). Each pixel consists of a 250 ?m square cell 
chamber, two side channels for medium and sample introduction, sandwich valves to isolate 
adjacent pixels and a neck valve to isolate the pixel from the side channels. Each pixel of the 
biodisplay can be programmed with a different bacterial strain. Standard microarray spotting 
was used to array bacterial cells or spores on an epoxy-coated glass slide. E. coli was spotted 
in medium containing 10% glycerol to preserve cell viability, as we observed that dried E. 
coli spots failed to regrow after spotting. B. subtilis spores could be spotted in water without 
addition of glycerol. The bacterial array was then aligned to the microfluidic chip and 
bonded at 37°C for 1 hour. 
 
 
 Figure 4.1: Biodisplay schematic and use. (a) Design of the two-layer microfluidic device 
(control channels in blue and flow channels in green). The device is composed of 16 rows and 
48 columns for a total of 768 biopixels. Each pixel consists of a spotting chamber (1), 
chamber valve (2), sandwich valves (3) and side channels (4). The side channels in turn can 
be specifically addressed using the side channel valves (5). A bacterial cell array is spotted on 
a glass slide and aligned with the PDMS chip. (b) The culturing sequence consists of 3 steps: 
i) flowing medium with the chambers closed (10 minutes), ii) incubation with the sandwich 
valves closed and chamber valves open (45 minutes), and iii) flowing lysis buffer with the 
chamber closed (10 minutes). (c) The sampling sequence consists of 4 steps: i) flowing the 
medium in both side channels (10 minutes), ii) flowing the sample in one side channel (10 
minutes), iii) incubation with both medium and sample (45 minutes), and iv) flowing lysis 
buffer (10 minutes). The sequence is than repeated continuously for the extent of the 
experiment. (d) The biodisplay can be imaged using a standard research grade epi-fluorescent 
microscope, a USB fluorescent microscope, a cellphone camera, or by eye. 
?
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After assembling and bonding the biodisplay, cells were allowed to recover overnight 
using an automated culturing routine (Figure 4.1b). A medium reservoir was attached to the 
device and the waste outlet was connected to a receptacle containing 70% aq. EtOH to 
immediately sterilize and contain the device outflow. First, the entire device was loaded with 
medium by outgas priming [18]. Once the device was fully primed with medium, cells were 
cultured with the following three-step culturing routine: i) flowing medium through the side 
channels (10 minutes), ii) allowing medium to diffuse into the biopixels (45 minutes) and iii) 
flowing lysis buffer through the side channels (10 minutes). Whenever fluid was flowed 
through the side channels, the biopixel chambers were sealed off from the side channels 
using a set of valves. In step (ii) the biopixel valves were opened to allow diffusion of 
molecules in and out of the biopixel chamber. During this step, individual pixels were 
isolated from one another by the sandwich valves. The lysis segment of the culturing routine 
prevented biofilm and microcolony formation outside of the biopixels [19]. By actively 
preventing accumulation and growth of cells in areas other than the biopixels we prevented 
device clogging and allowed experiments to proceed for several days; the longest experiment 
conducted here lasted one week. Culturing was performed at 37ºC using a thermo glass plate 
(Okolab). Culturing at 37ºC increases growth rate, leading to faster accumulation of 
biomass, but was otherwise not required and incubation at room temperature was also 
possible. After overnight culturing, each bacterial spot had outgrown, and populated its 
dedicated biopixel. We did not observe any contamination resulting from microarraying. 
Cells occasionally populated empty biopixels during culturing, which was avoided by 
spotting a non-fluorescent E. coli strain in otherwise empty biopixels. 
Once the biodisplay was online, we switched from the culturing routine to a sampling 
routine that enables frequent testing of a liquid sample (Figure 4.1c). The sampling routine 
was identical to the culturing routine, with an additional step added prior to diffusive mixing 
of the pixel and side channels. After flowing medium through both side channels, the sample 
was flowed through one of the side channels. During the diffusion step, both the medium 
and the sample were allowed to diffuse into the biopixel chambers. This process allowed us 
to aspirate a sample directly from an environmental source, rather than having to premix it 
manually with the medium solution. By using a dedicated sampling port, it was possible to 
sample a source for extended periods of time in 75 minute intervals without user 
interference.  
We employed a standard research grade epi-fluorescent microscope (Nikon) and a 
handheld, low-cost USB fluorescent microscope (Dino-Lite) for device readout and 
quantitation (Figure 4.1d). The standard epi-fluorescent microscope equipped with a 
motorized stage was programmed to image each biopixel individually whereas the handheld 
USB microscope could image either the entire display or acquire several sub-sections. Both 
approaches were used to acquire time course and endpoint measurements. We also 
demonstrated that the biodisplay could be observed directly by eye using a LED flashlight 
and an emission filter, and images could be acquired using a standard cellphone camera. 
?
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4.2.2 - Multiplexed characterization of bacterial strains 
We tested the biodisplay device by culturing and characterizing nine E. coli strains 
engineered to induce GFP or RFP expression in response to arabinose (Table 4.1). These 
strains were obtained from the iGEM registry of standard biological parts and were 
generated by various student teams. The fluorescent protein genes were under the regulation 
of a pBAD promoter or derivatives thereof. We programmed the biodisplay with the nine 
strains, each strain filling 2 columns of the device for a total of 32 pixels per strain. Strains 
were induced with arabinose after overnight culturing at 37°C. Induction was performed at 
room temperature (23-24ºC) (Figure 4.2a) or 37ºC (Figure SI 4.1). Room temperature 
induction was used in order to assess the performance of the biodisplay and cell-based 
sensors at ambient temperature in order to reduce platform complexity by eliminating the 
need for a temperature control element. 
We designed the biodisplay device so that it was possible to specifically address four sets 
of four rows with a different solution. We used this modality to characterize each strain 
against four arabinose concentrations: 0.006 mM, 0.066 mM, 0.666 mM, 6.66 mM 
(0.0001%, 0.001%, 0.01% and 0.1% w/v) arabinose in LB medium. Altogether, we tested 36 
strain – inducer combinations by measuring nine strains in response to four arabinose 
concentrations with eight technical repeats for each combination. The biodisplay was placed 
on an automated research-grade fluorescent microscope and imaged over time. 
We performed two consecutive 24 hour inductions, with the second induction starting 2.5 
days after the end of the first (Figure 4.2). Upon induction we observed a measurable signal 
in all strains. All three of the GFP strains showed a strong response to 6.66 mM arabinose 
while only strain #3 induced highly in response to 0.666 mM. Strains #1 and #2 induced to 
low levels in response to 0.666 mM and failed to induce to appreciable levels at lower 
arabinose concentrations, whereas strain #3 also induced in the presence of 0.066 mM 
arabinose. These results showed that strains #2 and #3 could be used in combination to 
distinguish three different inducer concentrations ranging over 3 orders of magnitude. All 
RFP strains induced expression to differing degrees in response to 6.66 mM arabinose and in 
the cases of RFP strains #2-6 also to 0.666 mM arabinose. All strains, with the exception of 
strain GFP_1 slowly decreased in intensity during the 2.5 days de-induction period. Strain 
GFP_1 exhibited a transient expression profile with signal beginning to decrease during the 
induction phase. GFP_1 is also the only strain that failed to induce during the second 
induction when cultured at room temperature but induced well in the second induction when 
cultured at 37ºC (Figure SI 4.1). The transient expression profile can be attributed to the 
DH5-? background used and the presence of a LVA protease tag which is not present in any 
of the other strains tested. 
Using the same approach we tested nine engineered arsenic responsive bacterial strains 
[20], [21]. We chose arsenic responsive strains, for use in a biodisplay for low-cost, 
continuous environmental arsenic monitoring. After overnight growth, we flowed LB 
medium with 0 ?g/l, 10 ?g/l, 100 ?g/l and 500 ?g/l sodium-arsenite for 24 hours and 
quantitated GFP expression over time. The experiment was performed at room temperature. 
Strain EDI_as_4 in particular showed high expression of GFP and detected sodium-arsenite 
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down to 10 ?g/l (Figure SI 4.2). We thus chose this strain for all further arsenic sensing 
applications. 
 
 
Figure 4.2: Using the biodisplay for strain characterization. (a) Fluorescence kymograms 
of nine arabinose-sensing E. coli strains. Shown is a representative biopixel for each strain 
and condition tested. The strains were induced twice for 24 hours with 0.006 mM, 0.066 mM, 
0.666 mM and 6.66 mM arabinose. (b) Quantitative analysis of fluorescence pixel intensities 
for each strain under four arabinose concentrations. The yellow background denotes the two 
induction periods. Each data point represents the average of eight pixels with error bars 
representing to the std. deviation of the means. 
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This series of experiments demonstrated that our biodisplay is a viable high-throughput 
platform for long-term culturing and characterization of bacterial strains. Theoretically, up to 
768 strains can be characterized in parallel on this platform under dynamically changing 
media conditions [15], which is otherwise difficult to achieve using standard microplate 
batch cultures or low-throughput microfluidic devices. 
We also performed an experiment demonstrating that the biodisplay is able to sense 
arabinose after a period of continuous operation. The arabinose sensitive strains were spotted 
and four different concentrations of arabinose were flowed after 3 days (Figure 4.3).  
 
 
Figure 4.3: One delayed arabinose induction. Quantitative analysis of fluorescence pixel 
intensities for each strain under four arabinose concentrations. The yellow background 
denotes the induction period. Each data point represents the average of eight pixels with error 
bars representing to the std. deviation of the means. 
?
The experiment has been performed at room temperature. An increase of the signal has 
been observed as soon as the medium spiked with different arabinose concentrations is 
flowed through the device. 
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4.2.3 - Biodisplay 
High levels of arsenic in groundwater are common in a number of countries including China, 
India, and the USA. Not only is arsenic a concern in water supplies, high arsenic levels have 
also been found in a number of food sources [22], particularly rice [23], [24]. In Bangladesh, 
an estimated 20 – 45 million people are affected by arsenic levels that exceed the national 
standard of 50 ?g/l and the WHO / EPA standard of 10 ?g/l [25]. Worldwide it is estimated 
that over 200 million people are exposed to unsafe arsenic levels of 10 ?g/l or above [26]. 
Arsenic also tops the ATSDR substance priority list [27], which lists those substances 
“determined to pose the most significant and potential threat to human health”. Our 
biodisplay could serve as a continuous environmental water monitor that is low-cost, readily 
deployable in resource limited settings, and easy to interpret. 
We programmed our biodisplay with an arsenic sensing E. coli strain (EDI_as_4) spelling 
“As”, the elemental symbol for arsenic, and a “skull and crossbones” symbol commonly 
used to warn of toxic substances (Figure 4.4). All pixels not programmed with the arsenic 
sensing strain were programmed with a non-fluorescent strain to prevent invasion and cross-
contamination by the arsenic sensing strain. After overnight growth, sodium-arsenite in tap 
water was sampled by the device using the sampling routine described above. The biodisplay 
was kept at room temperature for the entire duration of the sampling routine. Using the 
research grade fluorescent microscope for readout, the biodisplay detected as little as 10 ?g/l 
sodium-arsenite, and 20 ?g/l sodium-arsenite was detected with the handheld low-cost 
fluorescent USB microscope (Figure SI 4.3). Fluorescent signal and the appearance of the 
“As” and “skull and crossbones” symbols was detected after 10 hours by the research grade 
microscope (Figure SI 4.4). After 24 hours a strong fluorescent signal had developed that 
could be easily imaged with a low-cost handheld USB microscope. A negative control 
biodisplay, which was run under identical conditions but exposed to tap water without added 
arsenic showed no detectable fluorescent signal. 
 
 
Figure 4.4: Biodisplay for arsenic sensing. Arsenic-responsive E. coli was spotted spelling 
“As” and forming a “skull and crossbones” symbol. 20 μg/l of sodium-arsenite in tap water 
was sampled and images were acquired using Nikon and USB microscopes after 24 hours. 
?
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Given the large number of programmable pixels and high pixel density on our biodisplay 
we explored the possibility of generating a biodisplay that could sense and report the 
presence or absence of multiple substances in a sample (Figure 4.5a).  
 
 
Figure 4.5: Biodisplay for arabinose and arsenic sensing. (a) Multiplexed detection of 
arabinose (blue) and arsenic (red) by two E. coli strains that were spotted to display a 
“smiley” and a ”skull and crossbones” symbol, respectively. Nikon and USB images of the 
chip were acquired after flowing all combinations of 6.66 mM arabinose and 100 μg/l 
sodium-arsenite in tap water in four independent experiments. Scale bars: 750 μm (b) 
Quantitation of GFP intensity, after 24 hours of induction, measured using the USB 
microscope. (c) The device exposed to both arsenic and arabinose, was imaged using a 
mobile phone. The image was obtained using the illumination with blue LEDs and a band-
pass filter, placed in front of the cellphone camera. Scale bar: 3.5 mm. 
?
We selected the same arsenic sensing strain as above and the iGEM GFP_3 strain for 
arabinose sensing. The arsenic sensing strain was spotted in the form of a “skull and 
crossbones” pattern whereas the arabinose sensing strain was spotted in a “smiley” pattern. 
We performed four separate experiments exposing a new biodisplay to one of the four 
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possible combinations of arsenic and arabinose. After sampling for 24 hours, the biodisplay 
accurately reported on the presence / absence of these two small molecules (Figure 4.5a, b). 
We note that the arsenic-sensing strain used (EDI_as_4) was engineered to be tunable by 
arabinose, explaining the difference in intensity of the “skull and crossbones” symbol 
between experiments sampling arsenic and arabinose versus arsenic alone [20]. 
 The patterns could be readily imaged using a research grade and USB fluorescent 
microscope. Because of the ease with which the symbols could be visualized we also tested 
whether the device could be imaged directly with a cellphone using a blue LED flashlight for 
illumination and a fluorescence emission filter held in front of the cellphone camera. Both 
symbols could readily be imaged with this simple setup (Figure 4.5c). The symbols could 
also be seen by eye using the flashlight and emission filter. Imaging was performed in an 
illuminated laboratory during daylight hours, with a small black curtain shielding the device 
from direct sunlight (Figure 4.5c, Figure SI 4.5). 
4.2.4 - Spores enable long-term storage 
In order to develop a biodisplay that can withstand long-term storage and shipping without 
requiring a cold chain or special conditions we explored the use of bacteria spores. Bacterial 
spores are well known for their incredible robustness to adverse environments [28], [29] and 
thus would be ideal for programming the biodisplay. 
We generated spores from two B. subtilis strains, each containing a genomically 
integrated Phy-spank promoter driving the expression of either mCherry or GFP. The spores 
were spotted onto glass slides together with B. subtilis and E. coli cells. The slides were 
aligned and bonded to a microfluidic device. These biodisplays were then stored for one day 
or one month at 40ºC and 80ºC. After the storage period we introduced LB medium (Figure 
4.6a, b). Neither E. coli nor B. subtilis cells could be recovered after any storage condition 
tested. Only when spotted in the presence of glycerol and without an extended storage period 
could E. coli and B. subtilis cells be recovered. B. subtilis spores, on the other hand, 
germinated after all storage conditions, notably even after incubation at 80ºC for one month. 
Germination was observed as early as 1.5 hours after the start of the culturing routine. To 
test whether a spore-based biodisplay retains sensing capability after storage at 80ºC for one 
month, we induced expression with 1 ?M IPTG and observed a rapid increase of 
fluorescence within 90 minutes. B. subtilis biopixels not exposed to IPTG remained non-
fluorescent (Figure 4.6c). 
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Figure 4.6: Spore biodisplay. (a) Comparison of E. coli cell, B. subtilis cell and B. subtilis 
spore recovery under different storage conditions. Each table entry represents the number of 
chambers with observed growth divided by the total number of spotted chambers for a 
specific temperature and time condition. (b) Bright-field images of a magnified view of the 
central part of representative pixels after storage at 80?C for 1 month. Images were acquired 
immediately after spots were resuspended in medium and after 5 hours incubation at 37?C. (c) 
Time-lapse images of germinated Phy-spank-mCherry B. subtilis spores after storage at 80ºC 
for one month. Cells were induced with 1 μM IPTG. 
?
To decrease the risk of environmental biological and chemical release, the whole spore 
biodisplay with attached tygon tubings to the inlets and outlets of the chip was embedded 
into PDMS (Figure SI 4.6a). No effect on the spore germination and B. subtilis cells 
induction was observed (Figure SI 4.6b, c). Increasing the flow pressure from 20 kPa to 140 
kPa as well as the actuation pressure of the control valves from ~70 kPa to 172 kPa did not 
perturb the functionality of the device, demonstrating its improved tolerance to higher 
applied pressures.  
?
4.3 - Conclusions 
We developed a bio-hardware device by combining engineered bacterial strains with a 
microfluidic chip. The resulting biodisplay consists of 768 independently programmable 
biopixels and we showed that it can culture bacterial strains for extended periods of time. 
Continuous culturing, with the capability of dynamically changing media makes the 
biodisplay a useful platform for high-throughput bacteria cell analysis (manuscript arising) 
and may find application in high-throughput screening and characterization of synthetically 
engineered bacterial strains. 
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Biological systems are powerful sensors, but challenging to deploy for several reasons. 
First, engineered biological systems generally need to be cultivated under fairly well 
controlled conditions, and often require the presence of antibiotics in order to maintain the 
synthetic network. Second, a major concern limiting the applicability of synthetic systems is 
the possible escape of genetically modified cells into the environment. Not only is the escape 
of GMOs a concern, but also the release of genetic material, which could readily be taken up 
by environmental bacteria through horizontal gene transfer. Our biodisplay solves both 
issues by providing a platform that enables long-term culturing, while eliminating release of 
genetic and chemical material into the environment. The small scale of the device requires 
low quantities of medium and antibiotics: ~2 ml for a 6 day experiment. The device outflow 
is sterilized and collected to prevent environmental contamination of biological and chemical 
components.  
The ability to culture bacterial sensors on the biodisplay for extended periods of time 
with frequent readout makes the biodisplay a useful environmental monitoring tool. We have 
shown that our biodisplay can detect arabinose and sodium-arsenite in tap water using 
bacterial strains previously engineered by other research groups [20], [30] and student teams 
[31]. A large number of heavy metal sensors have already been engineered, including arsenic 
[32] [33], mercury [33], and lead sensors [34]. Information processing systems also exist, 
including genetic toggle switches [35], logic functions [36], band-pass filters [37], and event 
counters [38]. By combining event counters or toggle switches with sensors it is possible to 
implement memory, which could be useful in instances when the biodisplay can be 
monitored only intermittently, but a transient contamination should be logged and reported. 
The use of band-pass filters would enable the development of a biodisplay that reports the 
concentration of an analyte without requiring quantitative analysis of the reported signal. 
The biodisplay can also reduce the complexity of engineered strains, since functions can 
potentially be distributed amongst several strains [39]. For example, to generate a sensor that 
senses and reports the presence/absence of three different substances wouldn’t require 
incorporation of all three functions into a single strain but could instead be implemented in 
three individual strains. It should also be possible to develop chemiluminescent biodisplays 
or color biodisplays using chromogenic proteins. Communication between pixels as 
previously demonstrated using hydrogen peroxide [17] could also be used to couple sensing 
biopixels, logic biopixels, and reporter biopixels. 
Unlike previous biopixel arrays [17] where each pixel contains the same bacterial strain, 
each pixel on our display can be specifically programmed with a different strain, drastically 
increasing the multiplexing capacity and information content of our biodisplay with a 
maximum of 768 unique strains, each of which could contain multiple, genetically encoded 
functions. A previous demonstration of integrating an E. coli arsenic biosensor in a 
microfluidic device was limited to a single culture, employed a complex scheme that 
decoupled culturing from measurement, and used a research-grade fluorescent microscope 
for readout [40]. A scheme called InfoBiology was used for the transmission of information 
using arrays of bacterial cells spotted on microtiter sized agar plates [41]. 144 colonies of a 
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handful of strains were spotted in this scheme, but lacked integration with a microfluidic 
device for cell culturing and environmental sampling. 
We have previously developed a low-cost, portable hardware system that contains all 
necessary components for microfluidic device operation, making the biodisplay readily 
deployable in resource limited settings [42]. By using bacterial spores the biodisplay can be 
stored and shipped under ambient conditions and is viable for extended periods of time. The 
material cost of the biodisplay itself is negligible at less than 1 USD per device. In this 
particular example a bio-hardware platform applied to continuous environmental monitoring 
of arsenic levels in water could replace a 26'5000 USD instrument with an annual running 
cost of over 3'5000 USD (Oval7000, Modern Water Monitoring Limited). The relatively 
slow response time of our biodisplay is acceptable in this and other applications, where 
continued chronic exposure of a substance is to be avoided. For time critical applications the 
response time of the biosensors would need to be improved, for example by developing 
phosphorylation based sensors and reporters rather than transcriptional based genetic 
networks [43]. 
Programmable biopixel displays drastically simplify device readout and interpretation. 
Instead of reporting the presence of arsenic using a display-wide pattern of signal 
oscillations [17], our biodisplay generates an easy to understand “skull and crossbones” 
symbol. We showed that this concept can be easily multiplexed using different symbols to 
report the presence of multiple small molecules. The number of biopixels is scalable with 
previous work on two layer polydimethylsiloxane (PDMS) chips having demonstrated up to 
4'160 unit cells per device [44], [45]. Immediate optical readout without specialized 
equipment combined with the fact that computing and decision-making steps are conducted 
by the biodisplay itself make it low-cost, easy to deploy, and easy to interpret. Bio-hardware 
hybrid devices therefore combine the advantages of biological systems with the advantages 
of mechanical, electrical and optical systems. The ability to engineer biological systems on 
the molecular level and combine them with novel hardware opens new opportunities for how 
biological, mechanical, electrical and optical systems are integrated and the types of 
functions they can perform. 
 
4.4 - Methods 
4.4.1 - Materials 
All bacterial strains and plasmids used in the study are listed in  Table 4.1. Cells for arsenic 
detection were a gift from Baojun Wang (University of Edinburgh): pBW103ParsR-
Amp30C (Addgene plasmid # 78638), pBW300ParsR-Amp32T (Addgene plasmid # 78652), 
pBW102ParsR-Amp32C (Addgene plasmid # 78637) and pBW101ParsR-gfp (Addgene 
plasmid # 78636). LB medium was purchased from Applichem Panreac (A0954). L-(+)-
Arabinose (A3256-100G), 0.05M (35000-1L-R) and chloramphenicol (23275) were 
purchase from Sigma. Kanamycin sulfate (T832.1) was bought from Carl Roth. Isopropyl-?-
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D-thiogalactoside for spore induction was purchased from Roche. Schaeffer and Fulton 
Spore Stain Kit was bought from Sigma Aldrich. 
4.4.2 - Device fabrication 
Device molds were made using standard photolithography techniques. The mold for the 
control layer was made using GM 1070 SU-8 photoresist (Gersteltec Sarl, Switzerland) with 
a height of 30 ?m. The flow layer was made with AZ9260 photoresist (Gersteltec Sarl, 
Switzerland) with a thickness of 14 ?m. A Suss MJB4 single side mask aligner was used to 
expose the wafers. The flow mold was baked for 2 hours at 135°C to anneal the flow 
channels. The molds were then treated with chlorodimethylsilane (DMCS) prior to being 
exposed to PDMS (Sylgard 184). The double layer microfluidic device were made by using 
multilayer soft lithography [46]. For the flow layer, PDMS was prepared with a ratio of 20:1 
(part A:B) and spin coated with a speed of 3000 rpm for 1 minute, in order to get a thickness 
in the range of 20 – 40 mm. The control mold was placed in a petri dish and coated with a 
5:1 ratio of PDMS, in order to get a ~ 0.5 cm thick device. Both layers were baked for 30 
minutes at 80°C. Then the control layer was cut and peel of from the petri dish and place on 
top of the flow. The alignment of the two layer was performed by eyes using a 
stereomicroscope; markers, placed all around the main structure of the device, help to 
understand when the alignment is done After alignment the two PDMS layers were baked 
for an additional 1.5 hours at 80°C. The chip was then aligned to a spotted glass slide. 
4.4.3 - Cell culture, transformation and spore formation  
E. coli and B. subtilis cells were cultured in LB medium at 37°C and 200 rpm with 
appropriate antibiotics, when required. All plasmid transformation and E.coli cell studies 
were performed in DH5-? cells. B. subtilis sporulation was performed as described 
previously [47]. For spore enrichment, a three day old B. subtilis cell suspension was 
centrifuge for 1 min at 15000 rpm, the pellet was washed three times with water and 
Schaeffer and Fulton spore staining was performed to verify the presence of spores. 
4.4.4 - Cell arraying 
Overnight cultures of E. coli and B. subtilis were centrifuged for 5 min at 3000 rpm. For the 
E. coli display the cell pellet was resuspended in 100 ?l LB with 10% glycerol and 
appropriate antibiotics. For the spore biodisplay spores were resuspended in water. Cell 
suspensions and B. subtilis spore solutions were plated in conical, polypropylene 96-well 
plates. The samples were spotted with a 0.7 nl delivery volume pin (946MP2B Arrayit) on a 
glass slide by using a microarray robot (QArray2, Genetix). Glass slides were coated with 
epoxysilane (3-Glycidoxypropyl-dimethoxymethylsilane 97% AC216545000 Acros 
organic). The spotting parameters were as follows: 100 ms inking time, 10 ms stamping 
time, max number of stamps per ink 30. A wash procedure was included that consisted of 
washing the spotting pin with 70% ethanol for 2 s, washing with water for 2 s each followed 
by pin drying. Depending on the spotting pattern and number of samples used the spotting 
time varied between 10 to 20 minutes.  
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4.4.5 - Cell-display culturing 
The E. coli array was aligned to a PDMS chip and incubate for 1 hour at 37°C. The spore-
array was aligned to a MITOMI [48] PDMS chip and incubated depending on the 
experimental procedure as follows: 40°C for 1 day, 40°C for 1 month, 80°C for 1 day, or 
80°C for 1 month. After the incubation step the devices were placed on a temperature-
controlled glass plate (H401-NIKON-TI_SR_GLASS/H401_T_CONTROLLER; Okolab) at 
37°C. Tygon tubes were filled with deionized water and connected to inlets of the control 
lines, pressure was applied in order to actuate the valves. For the E. coli display 68.9 kPa 
and 13.8 kPa were used, for the control and flow lines respectively. For the spore-display 
103.4 kPa and 24.1-27.5 kPa were used instead. For the spore display we used a 768 unit cell 
MITOMI chip[48], but performed the same culturing routine as on the biodisplay device. 
For the cell-culturing and sampling routines a custom-written LabVIEW program was used. 
During the culturing, LB medium with appropriate antibiotics and lysis buffer containing 30 
mM of NaOH (06203-1KG Sigma Aldrich) and 12% SDS (L3771-100G Sigma) was used. 
Depending on the experimental procedure LB medium or water was supplemented with 
arabinose, sodium-arsenite, or IPTG. The level of arsenic in the tap water was measured by a 
colorimetric arsenic stip test kit (MQuant™ Arsenic  Test , Sigma Aldrich) with LOD of 5 
?g/l. No levels of arsenic, in the tap water, were detected by the kit. 
 
4.4.6 - Imaging 
Image acquisition was performed on a Nikon ECLIPSE Ti automated microscope equipped 
with a LED Fluorescence Excitation System and a Hamamatsu ORCA-Flash 4.0 camera 
controlled by NIS Elements. Images were taken at 40x magnification (SPlan Fluor, ELWD 
40x/0.60, ?/0.2, WD 3.6-2.8, Nikon) in fluorescent and bright field mode. Images of all 
biopixel units were stitched together using either the Grid/Collection Stitching plugin in Fiji 
or a custom-written Python script. Fluorescent measurements were performed using Genepix 
software. A FITC USB fluorescent microscope (AM4113T-GFBW, Dino-Lite) was used to 
acquire fluorescent images. Images of 9 sub-sections of the device were taken, using lower 
magnification (10x), and stitched. Pictures were also taken using a cellphone camera. A 
band-pass filter, centered at 530 nm with a 40 nm bandwidth, was placed in front of the 
camera of the mobile phone, and the LEDs of the FITC USB microscope were used for 
illumination of the biodisplay. 
?  
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4.5 - Supplementary 
4.5.1 - Biodisplay for strain characterization at 37°C 
 
Figure SI 4.1: Biodisplay for strain characterization at 37°C. Fluorescent intensity of GFP 
or RFP expression of nine different arabinose sensitive E. coli strains. The cells were induced 
twice with 4 different concentrations of arabinose (0.006 mM, 0.066 mM, 0.666 mM and 6.66 
mM). The yellow background indicates the induction intervals. The microfluidic chip was 
heated to 37°C during the experiment. 
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4.5.2 - Arsenic responsive E. coli 
?
 
Figure SI 4.2: Arsenic-responsive E. coli. EDI_as_4, was spotted on the chip and four 
different concentrations of sodium-arsenite in LB were sampled for 24 hours. GFP expression 
was monitored over time using a Nikon microscope. 
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4.5.3 - Arsenic biodisplay –different arsenic concentrations 
?
 
Figure SI 4.3: Arsenic biodisplay. (a) Fluorescent images taken using Nikon and USB 
microscope after 24 hours of induction with different concentrations of sodium-arsenite (100 
?g/l, 50 ?g/l, 20 ?g/l, 10 ?g/l and 0 ?g/l). Each concentration was sampled in different 
devices. (b) Quantitation of the fluorescent signal, after 24 hours of induction and measured 
with the Nikon microscope. 
?  
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4.5.4 -  Arsenic biodisplay over time 
?
?
Figure SI 4.4: Arsenic biodisplay over time. Arsenic-responsive E. coli was spotted in a 
“As” and a “skull and crossbones” pattern. 20 μg/l of sodium-arsenite in tap water was 
sampled and GFP expression monitored over time using a Nikon microscope. 
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4.5.5 - Cellphone image acquisition 
?
?
Figure SI 4.5: Cellphone image acquisition. (a) The microfluidic chip was illuminated using 
the LEDs of a USB microscope (excitation at 480 nm), a band-pass filter centered at 530 nm 
with a 40 nm bandwidth was placed in front of the camera of the cellphone. (b) The same 
device was illuminated by white light and imaged using the cellphone and emission filter as 
in (a). Scale bar 1 cm. 
? ?
????????????????????????
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4.5.6 - Embedded device 
?
Figure SI 4.6: Embedded spore biodisplay. (a) Photos comparing the spore biodisplay and 
the embedded PDMS spore biodisplay. (b) Bright-filed images of representative chambers 
showing the spores outgrowth. Images are acquired immediately after spot resuspension with 
medium and 3 hours incubation at 37°C. (c) Time-lapse images of germinated Phy-spank-
mCherry B. subtilis spores after induction with 1 μM IPTG. 
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4.5.7 - List of strains used in this work 
?
Identifier Name Host Strain Resistance Inducer Reporter 
BBa_I13517 iGEM RFP_1 E.coli DH5? Chloramphenicol Arabinose       RFP 
BBa_K1333301 iGEM RFP_2 E.coli DH5? Chloramphenicol Arabinose RFP 
BBa_K1333300 iGEM RFP_3 E.coli DH5? Chloramphenicol Arabinose RFP 
BBa_K577004 iGEM RFP_4 E.coli DH5? Chloramphenicol Arabinose RFP 
BBa_K577882 iGEM RFP_5 E.coli DH5? Chloramphenicol Arabinose RFP 
BBa_I13516 iGEM RFP_6 E.coli DH5? Chloramphenicol Arabinose RFP 
BBa_K750000 iGEM GFP_1 E.coli DH5? Chloramphenicol Arabinose GFP 
BBa_K584000 iGEM GFP_2 E.coli DH5? Chloramphenicol Arabinose GFP 
BBa_K577881 iGEM GFP_3 E.coli DH5? Chloramphenicol Arabinose GFP 
pBW101ParsR-
gfp (78636) 
EDI_as_1 E.coli DH5? Kanamycin Arsenic GFP 
pBW102ParsR-
Amp32C (78637) 
EDI_as_2 E.coli DH5? Kanamycin Arsenic GFP 
pBW103ParsR-
Amp30C (78638) 
EDI_as_3 E.coli DH5? Kanamycin Arsenic GFP 
pBW300ParsR-
Amp32T (78652) 
EDI_as_4 E.coli DH5? Kanamycin Arsenic GFP 
pIIUN gfp UNIL_1 E.coli DH5? Kanamycin Arsenic GFP 
pAAUN gfp UNIL_2 E.coli DH5? Kanamycin Arsenic GFP 
pVUN gfp UNIL_3 E.coli DH5? Kanamycin Arsenic GFP 
pLtet0UN gfp UNIL_4 E.coli DH5? Kanamycin Arsenic GFP 
pPR arsR abs gfp UNIL_5 E.coli DH5? Kanamycin Arsenic GFP 
BGSC 3A40 Bacillus 
subtilis subsp. 
Subtilis 
amyE::Physpan
k-mCherry 
B. subtilis subsp. 
subtilis 
 IPTG mCherry 
  
BGSC 3A39 
 
Bacillus 
subtilis subsp. 
Subtilis 
amyE::Physpan
k-GFP 
B. subtilis subsp. 
subtilis 
 IPTG 
 
GFP 
 
 
?
 Table 4.1: List of plasmids and strains used in this work. 
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  Chapter 5
Conclusions and outlook 
In this work, microfluidic platforms for multiplex immunoassay-based diagnostics and for 
environmental sensing have been developed. For both applications double layer microfluidic 
devices and spotting techniques have been exploited for creating multiplexed arrays of 
antibodies (for the immunoassay) and bacteria (for the environmental monitoring). 
 
5.1 - Microfluidics for high-throughput immunoassay analysis  
For the immunoassay application, we developed a high-throughput platform for protein 
interactions. The device enables 1’536 independent assays to be performed simultaneously. 
It is composed of 384 independent units, each of which can be addressed with a different 
antibody pair. Each unit contains four MITOMI buttons for analyzing four different samples. 
The stability of the device has been tested for long time periods (up to 1 month) at 40°C and 
according to performance tests, there is no significant difference between fresh and stored 
chips. The possibility to store the device for extended times, allows the device to be pre 
assembled before the analysis is performed making it suitable for academic and clinical 
applications.  
The platform has been validated for the detection of four biomarkers and as well as for 
combinatorial analysis, in order to identify functional antibody pairs. Larger scale screening 
can be performed in the device, like the analysis of large protein libraries to search for new 
biomarkers for diagnosis, prognosis or to monitor therapy.  
This platform would allow a drastic reduction in the cost of that study, not only for 
diagnostics but also for systems immunology and system biology applications. In fact the 
drastic reduction in the consumption of antibodies allows us to perform ~100’000 assays 
using ~100 ?l of antibody stock solution. 
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Two drawbacks of the first generation of this system are the experimental time and the 
sensitivity. The long experimental time is mostly due to the diffusion time of the antibodies 
from the spotting to the reaction chamber. The total experimental time, considering the 
surface chemistry (1.5 hour), the incubation of primary and secondary antibodies (6.5 hours), 
the flowing of four samples (1.3 hours) and the washing steps, is about 10 hours. To 
overcome this limitation, a peristaltic pump, between the spotting chamber and the assay 
chamber, has been introduced in order to speed up the mixing of the antibodies instead of 
relying on diffusion. This second microfluidic chip design allowed us to perform the entire 
experiment in 2.5 hours. 
Other requirements have been taken into consideration for the design of the second chip: 
low sensitivity, broad dynamic range, portability, and low sample volume. The device is 
composed of 16 independent units, each unit containing one MITOMI button. In order to 
improve the limits of detection a digital ELISA has been exploited and the MITOMI buttons 
have been patterned with femtoliter wells. The obtained sensitivity is in the femtomolar 
range, whereas the limits of detection using analog MITOMI buttons, is in the picomolar 
range, thus improving the limit of detection by 3 orders of magnitude. 
 Digital immunoassays are highly sensitive but do not allow the discrimination of high 
concentrations; indeed once the number of analytes increases, all the wells contain 
immunocomplexes and it is not possible to make a digital analysis (associating 1 to “on 
wells” and 0 to “off wells”). In order to increase the dynamic range, in one half of the 
device, the buttons were patterned with the digital wells and in the other half with standard 
analog MITOMI buttons. Combining the two techniques, digital detection for low 
concentrations and analog detection for high concentrations, we reached a dynamic range of 
5 orders of magnitude.  
Different kinds of sample matrices can be loaded into the device including, buffer, serum 
and whole blood. Only 5 ?L sample are required to perform the analysis and the sample does 
not need any pretreatment and it can be directly loaded into the chip after blood sampling.  
To make the employment of this platform feasible in a home-based setting or resource-
limited environment, we built a portable microfluidic diagnostic system (?FDS) able to 
actuate the valves and control the flow of reagents. Using an Arduino interface it is possible 
to select the valves, regulate the pressure or start an automated program to perform the 
different assays (detection of an antigen or antibody for analog, amp, or analog-amp 
reactions). Furthermore, we employed a low cost and portable USB fluorescent microscope 
to image the chip. The entire cost of the microfluidic control system, the USB microscope 
and the netbook is $2’628 USD, and the cost for the disposable microfluidic chip is $1 USD. 
The cost could be further reduced by replacing some components, such as new generation 
solenoid valves, which are cheaper and more compact than those currently used.  
In order to make the device more user-friendly, it could also be possible to replace the 
individual tubing for the control valves with “plug and play” multi-connectors, in order to 
interface the microfluidic device to multiple lines in a more convenient way. 
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So far the samples analyzed included mouse whole blood or human serum spiked with 
anti-Ebola, though it would also be interesting to test a clinical human sample. The platform 
could be applied further for the detection of multiple biomarkers, specific for a given disease 
especially for tests where the amount of sample is limited. For example, for the early 
diagnosis of Alzheimers, there is a set of biomarkers in the cerebrospinal fluid, which are 
recognized to be relevant [1], however the amount of available sample is too limited to 
conduct for several standard ELSA tests. 
5.2 - Bacteria biodisplay 
Multiplayer soft lithography has also been used for high-throughput culturing of bacterial 
cells. A different platform with 768 independent square units has been developed. Each 
chamber has been addressed with E. Coli cells using microspotting techniques. It is thus 
possible to have a multiplex array of cells with up to 768 different strains. After spotting the 
glass slide is aligned with a PDMS chip, stored for 1 h at 37°C and then connected with flow 
tubing, containing either media, lysis, or inducer solutions. The device can be employed for 
studying the high-throughput response of cells to different kinds or concentrations of 
inducer, in a unique device. A set of valves allows isolation of the chambers from each other 
and from the main channel, where the medium and lysis buffer are flown. Fresh medium and 
inducers diffuse periodically in the spotting cell, where the cells grow, and long term 
culturing is possible. As a proof of concept, nine different E. coli arabinose sensitive bacteria 
strains have been spotted. Different levels of the reporter protein have been observed 
depending on the different strain of cells and the concentration of arabinose. Different strains 
respond differently to the varying concentrations, such that low concentrations can only be 
detected from the more sensitive strains. Thus, it could be possible to spot different strains 
according to their sensitivity to obtain a progressive indication of the amount of an inducer 
molecule and discriminate the concentration in the sample based on which strain is 
producing the reporter protein. 
E. coli strains sensitive to arsenate have also been employed to monitor the presence of 
this molecule in tap water. The cells were spotted according to a cross bone and skull 
pattern, and when a certain level of arsenate, 10 ?g/L, is present in the solution (tap water), 
they produce GFP. The fluorescence signal can be detected using a low cost USB 
microscope making the entire system cheap and portable. Two different E. coli cells, 
sensitive to two different molecules (arabinose and arsenic) have been spotted in order to 
show the capability of performing multiplex detection. 
Transmission of pathogenic trough water is a global concern; and this platform can be 
used for a large screening of different heavy metals such as: arsenic, lead, mercury, and 
cadmium. Genetically engineered microorganisms for the detection of explosives have also 
been generated in order to detect 2,4,6-trinitrotoluene (TNT), for example[2]. Thus this 
device can be used to test the quality of groundwater reservoirs in the proximity of explosive 
manufacturing facilities, where the presence of residues of explosives could be found as a 
contaminant.  
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The device can also be employed for the detection of antimicrobials in food samples 
(such as milk, fish...). Several antibiotics are used by veterinarians or as food additives for 
growth promotion in the farming industry. Doses of antibiotics should be minimized to avoid 
resistance and to prevent the inclusion of allergenic antibiotics in the finished product, thus a 
control of food samples is necessary. For example, a bacterial strain sensitive to tetracycline 
can be employed for the detection of traces of the antibiotic in a fish sample [3] and the 
biodisplay could be used to perform the test.  
There are systems for the detection of environmental samples that require one test vial 
and they can be performed in a short time periods, but on the other hand they do not allow a 
multiplexed and continuous analysis of a sample source. Instead, with the biodisplay 
platform multiplexed parameters could be monitored over time. The devices containing the 
bacterial spores can be stored for longer time periods, compared to those with E. coli, so 
further investigation of these devices could overcome the limitation of device storage. 
In addition to its application towards environmental screening, the device can be 
employed for bacterial strain characterization. For example, it could be used as a tool for 
measuring expression dynamics in different cell strains [4], where screening a library of 768 
different strains (8x96-well-plate) could be achieved on a single device. 
?  
Chapter 5– Conclusions and outlook 
? 93 
Bibliography 
?
[1] B. Olsson et al., “CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic 
review and meta-analysis,” Lancet Neurol., vol. 15, no. 7, pp. 673–684, Jun. 2016. 
[2] B. Shemer, N. Palevsky, S. Yagur-Kroll, and S. Belkin, “Genetically engineered microorganisms 
for the detection of explosives’ residues,” Front. Microbiol., vol. 6, Oct. 2015. 
[3] T. Pellinen, G. Bylund, M. Virta, A. Niemi, and M. Karp, “Detection of Traces of Tetracyclines 
from Fish with a Bioluminescent Sensor Strain Incorporating Bacterial Luciferase Reporter 
Genes,” J. Agric. Food Chem., vol. 50, no. 17, pp. 4812–4815, Aug. 2002. 
[4] A. Zaslaver et al., “A comprehensive library of fluorescent transcriptional reporters for 
Escherichia coli,” Nat. Methods, vol. 3, no. 8, pp. 623–628, Aug. 2006. 
 
?
?? 95 
  Appendix A
?
Multiplexed serological detection of IgE and IgG for Allergy A.1 - 
detection 
In vitro testing of specific IgE reactivities for diagnosis of allergies is a routine serological 
analysis, while IgG detection, as a diagnostic indicator for allergies, remains controversial 
Due to the widespread incidence rate of allergies in the developed world there is 
considerable interest in developing novel assays and devices that perform sensitive, fast and 
multiplexed allergy tests [1]–[4] and do so in a POC or preferably a home-based setting. In 
serum the concentration of IgG is considerably higher than IgE, IgG thus readily 
outcompetes IgE for binding on the same immobilized allergen making IgE detection 
challenging [5], [6]. Commercial allergy tests are available based on lateral flow-based 
devices that allow the analysis of 10 IgE species, but require a large 110 ?l whole blood, a 
dedicated instrument for readout, and the quantification is qualitative or semiquantitative [7].  
We employed the 16 units microfluidic chip, introduced in chapter 3, to perform allergy 
test. Since only analog detection has been exploited, all the 16 buttons are analog MITOMI 
buttons. To demonstrate the ability of our device to perform detection of allergen-specific 
IgE and IgG we tested a human serum sample obtained from a patient diagnosed with peanut 
allergy. In principle our device can measure up to 16 different allergens specific Ig or up to 8 
different allergens for parallel quantitation of IgE and IgG. We programmed our device with 
two repeats of three different allergens: Arachis hypogaea allergen 2 (Ara h2), Felis 
domesticus allergen 1 (Fel d1), Dermatophagoides pteronyssinus allergen 2 (Der p2), and a 
negative control (Figure A.1a). The clinical serum sample (6 ml) was diluted 1:2 in an 
incubation buffer and flowed in the chip following the protocol described in the Materials 
and Methods section and IgE and IgG were detected as shown in Figure A.1b. In the top two 
rows of the device we measured allergen bound IgE and the bottom two rows of the device 
were used to detect IgG (Figure A.1c,d). We obtained clear signal for IgE and IgG bound to 
the recombinant allergen Ara h2, while the two other recombinant allergens Fel d1 and Der 
p2 showed no signal above the negative control. The signal obtained from IgG was 
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considerably stronger than that of IgE, as expected given the vastly different concentrations 
of these molecules in serum. Although we conducted readout of these devices with a 
research grade microscope, IgG levels were high enough to be observed directly using the 
fluorescence USB microscope indicating that a home-based, rapid allergy test could be 
developed. In the current form the diagnostic test is applicable in a POC setting to provide 
rapid and multiplexed analysis of a patient’s allergic profile.  
 
 
Figure A.1 Allergy detection: (a) Three biotinylated allergens (Ara h2, Fel d1, and Der p2) 
and a negative control (BSA) are spotted to allow multiplexed detection. (b) Schematic of the 
assay for the detection of IgG and IgE. (c) Quantification of IgE levels for a sample positive 
to peanuts allergy and the corresponding fluorescent images. (d) Quantification of IgG levels 
for a sample positive to peanuts allergy and the corresponding fluorescent images. Bars are 
means (n=2), with individual data points shown as dots (?). 
?
A.1.1 - Materials and Methods 
Three allergens: natural Ara h2, recombinant Fel d1, recombinant Der p2, and a BSA 
negative control were spotted in order to perform an allergy diagnostic test. The human 
clinical serum sample was diluted 1:2 (6.7 ?l in 13.4 ?l) with incubation buffer (0.05 M 
Tris/HCl pH 7.6, 0.15 M NaCl, Tween 20 0.02% v/v, BSA 1% w/v) [52]. After surface 
functionalization, 15 ?l of each reagent were loaded into tygon tubing, connected to the 
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device, and flowed sequentially at 3 psi for 10 minutes. First, 30.5 ?M (0.55 mg/ml) of Ara 
h2, 41.15 ?M (0.75 mg/ml) of Fel d1, and 42.8 ?M (0.6 mg/ml) of Der p2 were circulated 
through each unit cell by the S-shaped peristaltic pump for 20 minutes and immobilized in 
the button region coated via neutravidin. Then the clinical sample was flowed for 5 minutes. 
Next, 1:100 rabbit anti-human IgE in 2% BSA and 30 nM (11.7 ?g/ml) of anti-rabbit IgG PE 
conjugated antibody in 2% BSA were flowed on the top half of the device while 6 nM (2.4 
?g/ml) of goat anti-human IgG PE conjugated antibody in 2% BSA was flowed on the lower 
half for 10 minutes. Channels were washed with 0.005% Tween 20 in PBS after each step 
for 5 minutes. After the last washing step the buttons were closed with 25 psi pressure. 
Bright field and fluorescent images were taken using the Nikon microscope with an 
exposure time of 2000 ms for IgE and 300 ms for IgG.  
 
?
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